WO2022228495A1 - Preparation method for antibody-drug conjugate, and application - Google Patents
Preparation method for antibody-drug conjugate, and application Download PDFInfo
- Publication number
- WO2022228495A1 WO2022228495A1 PCT/CN2022/089726 CN2022089726W WO2022228495A1 WO 2022228495 A1 WO2022228495 A1 WO 2022228495A1 CN 2022089726 W CN2022089726 W CN 2022089726W WO 2022228495 A1 WO2022228495 A1 WO 2022228495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- compound
- group
- cancer
- tautomer
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract description 58
- 239000000611 antibody drug conjugate Substances 0.000 title abstract description 55
- 150000001875 compounds Chemical class 0.000 claims abstract description 259
- 239000003814 drug Substances 0.000 claims abstract description 110
- 229940079593 drug Drugs 0.000 claims abstract description 100
- 239000000203 mixture Substances 0.000 claims abstract description 91
- 150000003839 salts Chemical class 0.000 claims abstract description 73
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 65
- 239000012453 solvate Substances 0.000 claims abstract description 61
- 229940002612 prodrug Drugs 0.000 claims abstract description 60
- 239000000651 prodrug Substances 0.000 claims abstract description 60
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 125000004429 atom Chemical group 0.000 claims description 95
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 239000000427 antigen Substances 0.000 claims description 50
- 125000003545 alkoxy group Chemical group 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- -1 cyano, nitro, amino Chemical group 0.000 claims description 41
- 108010082974 polysarcosine Proteins 0.000 claims description 36
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 125000005647 linker group Chemical group 0.000 claims description 32
- 239000003446 ligand Substances 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 230000002209 hydrophobic effect Effects 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 125000002723 alicyclic group Chemical group 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 16
- 229960002173 citrulline Drugs 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 229960003767 alanine Drugs 0.000 claims description 15
- 229940024606 amino acid Drugs 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 230000000259 anti-tumor effect Effects 0.000 claims description 13
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 11
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 10
- 241001529936 Murinae Species 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 10
- 229940127093 camptothecin Drugs 0.000 claims description 10
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 10
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000006850 spacer group Chemical group 0.000 claims description 9
- 235000014393 valine Nutrition 0.000 claims description 9
- 229960004295 valine Drugs 0.000 claims description 9
- 239000004474 valine Substances 0.000 claims description 9
- 125000000732 arylene group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 229960002449 glycine Drugs 0.000 claims description 7
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960003121 arginine Drugs 0.000 claims description 6
- 235000009697 arginine Nutrition 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000013477 citrulline Nutrition 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 235000008729 phenylalanine Nutrition 0.000 claims description 6
- 229960005190 phenylalanine Drugs 0.000 claims description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 5
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical group OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 125000004956 cyclohexylene group Chemical group 0.000 claims description 4
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- OBVVKJDJORDBCH-CZDIJEQGSA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 OBVVKJDJORDBCH-CZDIJEQGSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 125000005649 substituted arylene group Chemical group 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 229960003646 lysine Drugs 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 120
- 238000006243 chemical reaction Methods 0.000 description 95
- 230000015572 biosynthetic process Effects 0.000 description 93
- 238000003786 synthesis reaction Methods 0.000 description 93
- 229940127121 immunoconjugate Drugs 0.000 description 90
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 81
- 239000000243 solution Substances 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 49
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
- 230000002829 reductive effect Effects 0.000 description 46
- 239000007787 solid Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 35
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 34
- 238000001542 size-exclusion chromatography Methods 0.000 description 32
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- 239000000562 conjugate Substances 0.000 description 28
- 239000000126 substance Substances 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 27
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 26
- 239000011780 sodium chloride Substances 0.000 description 25
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- 229950011276 belotecan Drugs 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 238000003756 stirring Methods 0.000 description 23
- 238000005859 coupling reaction Methods 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 230000003993 interaction Effects 0.000 description 21
- 229960000575 trastuzumab Drugs 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 20
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 19
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 18
- 239000012467 final product Substances 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 17
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 229950001460 sacituzumab Drugs 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 16
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 16
- BAORCAMWLWRZQG-UHFFFAOYSA-N genz 644282 Chemical compound COC1=C(OC)C=C2C(=O)N(CCNC)C3=C(C=C4C(OCO4)=C4)C4=NC=C3C2=C1 BAORCAMWLWRZQG-UHFFFAOYSA-N 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 238000011068 loading method Methods 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 238000004007 reversed phase HPLC Methods 0.000 description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000007429 general method Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 125000003827 glycol group Chemical group 0.000 description 12
- 239000000178 monomer Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 229950009429 exatecan Drugs 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229910052805 deuterium Inorganic materials 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 229950010966 patritumab Drugs 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 8
- 239000007821 HATU Substances 0.000 description 8
- 102100035486 Nectin-4 Human genes 0.000 description 8
- 101710043865 Nectin-4 Proteins 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 229960002087 pertuzumab Drugs 0.000 description 8
- 238000010791 quenching Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 229960003115 certolizumab pegol Drugs 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 6
- 101150117918 Tacstd2 gene Proteins 0.000 description 5
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 102000025171 antigen binding proteins Human genes 0.000 description 5
- 108091000831 antigen binding proteins Proteins 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 description 5
- 238000011033 desalting Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000005156 substituted alkylene group Chemical group 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 229910052722 tritium Inorganic materials 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- GSWKJIWKGSPISH-LRDDRELGSA-N (2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN1C(=O)C=CC1=O GSWKJIWKGSPISH-LRDDRELGSA-N 0.000 description 3
- NJQOCRDPGFWEKA-UHFFFAOYSA-N 1-(2-aminoethyl)pyrrole-2,5-dione;hydrochloride Chemical compound Cl.NCCN1C(=O)C=CC1=O NJQOCRDPGFWEKA-UHFFFAOYSA-N 0.000 description 3
- GBKPNGVKZQBPCZ-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)acetic acid Chemical compound OC(=O)CN1C(=O)C=CC1=O GBKPNGVKZQBPCZ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 206010029098 Neoplasm skin Diseases 0.000 description 3
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 3
- 241000720974 Protium Species 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229950000143 sacituzumab govitecan Drugs 0.000 description 3
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 229960002317 succinimide Drugs 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- JPJMNCROLRPFHI-QFIPXVFZSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)ON1C(=O)CCC1=O JPJMNCROLRPFHI-QFIPXVFZSA-N 0.000 description 2
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical class NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- JHUSQXBQANBSDC-UHFFFAOYSA-N 3-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCC(O)=O JHUSQXBQANBSDC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMLJIHNCYNOQEQ-REOHCLBHSA-N L-aspartic 1-amide Chemical compound NC(=O)[C@@H](N)CC(O)=O PMLJIHNCYNOQEQ-REOHCLBHSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- LJSOLTRJEQZSHV-UHFFFAOYSA-L potassium;sodium;hydron;hydroxide;phosphate Chemical group [OH-].[Na+].[K+].OP(O)([O-])=O LJSOLTRJEQZSHV-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VLXHZQQUTCVLGU-DEOSSOPVSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoate Chemical compound C([C@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)ON1C(CCC1=O)=O)C1=CC=CC=C1 VLXHZQQUTCVLGU-DEOSSOPVSA-N 0.000 description 1
- VEASIOSTNPNFHD-YFKPBYRVSA-N (2s)-6-amino-2-hydrazinylhexanoic acid Chemical compound NCCCC[C@H](NN)C(O)=O VEASIOSTNPNFHD-YFKPBYRVSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- BEVWMRQFVUOPJT-UHFFFAOYSA-N 2,4-dimethyl-1,3-thiazole-5-carboxamide Chemical class CC1=NC(C)=C(C(N)=O)S1 BEVWMRQFVUOPJT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- VVMAJDPAVPIJGJ-JZGIKJSDSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 VVMAJDPAVPIJGJ-JZGIKJSDSA-N 0.000 description 1
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- CGAVIHVJYPJDGP-UHFFFAOYSA-N 2-methylsulfonyl-1,3-benzothiazol-6-amine Chemical compound C1=C(N)C=C2SC(S(=O)(=O)C)=NC2=C1 CGAVIHVJYPJDGP-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- ULORBWQDLLOPLY-UHFFFAOYSA-N 4-(5-methylsulfonyl-1,3,4-oxadiazol-2-yl)aniline Chemical compound CS(=O)(=O)c1nnc(o1)-c1ccc(N)cc1 ULORBWQDLLOPLY-UHFFFAOYSA-N 0.000 description 1
- WXNSCLIZKHLNSG-MCZRLCSDSA-N 6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide Chemical compound CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[C@H](NC(=O)COCNC(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)CNC(=O)CCCCCN5C(=O)C=CC5=O)C3=C14)C2=O WXNSCLIZKHLNSG-MCZRLCSDSA-N 0.000 description 1
- RNWGZXAHUPFXLL-UHFFFAOYSA-N 6-nitro-3h-2-benzofuran-1-one Chemical compound [O-][N+](=O)C1=CC=C2COC(=O)C2=C1 RNWGZXAHUPFXLL-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- DALMAZHDNFCDRP-VMPREFPWSA-N 9h-fluoren-9-ylmethyl n-[(2s)-1-[[(2s)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound O=C([C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)NC1=CC=C(CO)C=C1 DALMAZHDNFCDRP-VMPREFPWSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010055400 Aspartate kinase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 102100029756 Cadherin-6 Human genes 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 101000794604 Homo sapiens Cadherin-6 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100162020 Mesorhizobium japonicum (strain LMG 29417 / CECT 9101 / MAFF 303099) adc3 gene Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HWCIETDQUHYHGQ-YHVCZDCZSA-N Tubulysin B Chemical compound C([C@@H](C[C@H](C)C(O)=O)NC(=O)C=1N=C(SC=1)[C@H](OC(C)=O)C[C@@H](N(COC(=O)CCC)C(=O)[C@@H](NC(=O)[C@@H]1N(CCCC1)C)[C@@H](C)CC)C(C)C)C1=CC=C(O)C=C1 HWCIETDQUHYHGQ-YHVCZDCZSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 101150042711 adc2 gene Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000005725 cyclohexenylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004978 cyclooctylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- IMMCOBGFCRNGBX-UHFFFAOYSA-N indeno[1,2-h]isoquinolin-1-one Chemical class C1=CC=CC2=CC3=C4C(=O)N=CC=C4C=CC3=C21 IMMCOBGFCRNGBX-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical class OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005550 pyrazinylene group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical class OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- HWCIETDQUHYHGQ-UHFFFAOYSA-N tubulysin B Natural products C1CCCN(C)C1C(=O)NC(C(C)CC)C(=O)N(COC(=O)CCC)C(C(C)C)CC(OC(C)=O)C(SC=1)=NC=1C(=O)NC(CC(C)C(O)=O)CC1=CC=C(O)C=C1 HWCIETDQUHYHGQ-UHFFFAOYSA-N 0.000 description 1
- 108010061146 tubulysin B Proteins 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
Definitions
- the present application relates to the field of biomedicine, in particular to a preparation method and application of an antibody conjugated drug.
- ADC Antibody Drug Conjugate
- Cytotoxics are essential for ADC drugs to play a role. Camptothecin drugs have great application prospects.
- the marketed ADC drugs Trodelvy and Enhertu use camptothecin drugs SN38 and DX-8951f as warhead molecules respectively.
- camptothecins finally prepared by camptothecins have greatly changed the properties of monoclonal antibodies, and the stability and half-life have been greatly attenuated.
- the objective response rate (ORR) confirmed by Enhertu reached 79.7%
- the objective response rate (ORR) confirmed by Enhertu was 37.0 for HER2-low expressing breast cancer %
- the treatment efficiency was significantly lower than that of breast cancer with high or medium expression.
- ADC drugs have new symptoms of toxic side effects, such as pneumonia and interstitial lung disease with the drug Enhertu.
- WO2020233174A1 discloses a class of camptothecin compounds containing a valine-citrulline (Val-Cit)-PAB linker, however, this molecule cannot be coupled with an antibody to obtain a qualified ADC molecule (in qualified ADC products).
- the aggregate content needs to be less than 5%). Therefore, there is an urgent need in the art to provide more suitable antibody-drug conjugates based on camptothecins (such as ixatecan, belotecan, etc.) to achieve efficient, simple and practical chemical preparation and conjugation, and Improve the pharmaceutical properties, metabolic properties, efficacy and safety of the existing antibody-conjugated drugs, such as improving the stability of ADC molecules, improving the therapeutic window, etc.
- the present application provides an antibody conjugated drug, an intermediate thereof, a preparation method and an application thereof.
- the antibody conjugated drug of the present application can realize the wide application of cytotoxic drugs in the field of ADC to treat tumor diseases.
- the main technical effect of the present application is that the provided novel linker can combine highly hydrophobic anti-tumor drugs, such as topoisomerase inhibitors isanotecan, belotecan, etc., with antibodies through specific chemical methods. Conjugation, the obtained conjugate has high hydrophilicity and stability.
- the antibody conjugate provided by the application is not easy to produce aggregates when the drug load is higher;
- the toxin molecules released in the present application are the prototype molecules of topoisomerase inhibitor ixatecan and belotecan. Tests show that the drug molecules have better properties than the drug derivatives released by similar ADC drugs. Good biological activity, safety and other drug-related properties. Therefore, the present application can improve the half-life of the drug in vivo and the concentration of the drug in the tumor tissue, thereby referring to the anti-tumor activity of the drug and/or improving the overall drug treatment window.
- the application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or A pharmaceutically acceptable salt, prodrug or solvate thereof, wherein the compound comprises the structure represented by the formula (C-Trop-2):
- L 1a is selected from the group consisting of optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted alicyclic groups, optionally substituted alicyclic heterocyclyl groups, optionally substituted arylene groups, and optionally substituted heteroarylene groups;
- L2 comprises optionally substituted polypeptide residues
- L 3 comprises an optionally substituted spacer group
- L 2 and/or L 3 comprise optionally substituted polysarcosine residues
- T contains the drug unit
- Ab is a ligand capable of binding Trop-2, and m is a number from 1 to 8.
- the application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof
- a pharmaceutically acceptable salt, prodrug or solvate
- the compound comprises a structure selected from the group consisting of:
- Ab is a ligand capable of binding Trop-2, and m is a number from 1 to 8.
- the application provides a pharmaceutical composition, which contains the compound described in any one of the application, or its tautomer, meso, racemate, enantiomer, A diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and optionally a pharmaceutically acceptable carrier.
- the present application provides a compound containing any one of the present application, or its tautomer, meso, racemate, enantiomer, diastereomer, Use of the mixture form thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and/or the pharmaceutical composition described in this application in the preparation of a medicament for treating and/or preventing tumors.
- the present application provides an antibody-drug conjugate, which is formed by coupling the compound of the present application with an antibody.
- the conjugates of the present application are covalently attached to one or more drug components.
- the antibody and drug of the present application are coupled covalently (eg, by covalent attachment to a linker, respectively).
- the present application provides a method for preparing an antibody-drug conjugate, wherein a pair of cysteine residues is generated by reduction of the disulfide chain in the hinge region of the antibody or antibody fragment, and the cysteine
- the sulfhydryl group in the acid residue undergoes a substitution reaction with the connecting group of the compound in the present application, such as maleimide group, and then the compound of the present application is connected to the cysteine sulfhydryl group of the antibody or antibody fragment to obtain an antibody -Drug conjugate
- the drug-antibody conjugation rate DAR (for example, m in this application) is controlled according to the reaction conditions, for example, it is usually between 2 and 8.
- m represents the molar ratio of cytotoxic drug molecules to Ab (also known as DAR, that is, drug-antibody coupling ratio), and m can be an integer or a decimal number, which can be understood as: a single monoclonal antibody molecule and cell
- the average molar ratio of drug molecules to monoclonal antibody molecules in the antibody-drug conjugate obtained after toxic drug conjugation can generally be determined by hydrophobic chromatography (Hydrophobic-Interaction Chromatography, HIC), reversed-phase high-performance liquid chromatography (Reverse high-performance liquid chromatography) phase HPLC, RP-HPLC), polyacrylamide-SDS gel electrophoresis (SDS PAGE, electrophoresis), liquid chromatograph-mass spectrometer (LC-MS), ultraviolet/visible spectroscopy (UV/Vis), etc. measured.
- the application provides a method for preparing the compound of the application, comprising the steps of:
- an amino acid active ester with an amino protecting group N1 with an amino acid to obtain an intermediate M1; in the presence of a condensing agent such as EEDQ (2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline)
- the intermediate M1 is contacted with substituted/unsubstituted p-aminobenzyl alcohol to obtain the intermediate M2; the N1 of the intermediate M2 is removed to obtain the intermediate M3; contacting a compound of an imide group to obtain an intermediate M4; contacting the intermediate M4 with bis(4-nitrophenyl) carbonate to obtain an intermediate M5; contacting the intermediate M5 with a drug unit .
- the N1 comprises fluorenylmethoxycarbonyl.
- the intermediate comprising the amino protecting group N2 is contacted with trifluoroacetic acid, followed by contact with acetyl polysarcosine contacts.
- the N2 comprises tert-butoxycarbonyl.
- the application provides a method of preparing a compound of the application comprising the steps of contacting the ligand with the compound of the application under conditions suitable for forming a bond between the ligand and the compound.
- the ligand is contacted with the compound of the present application in a mixture of buffer and organic solvent.
- the ligand is contacted with a compound of the present application at about 0 to about 37°C.
- the following step is included before contacting the ligand with the compound of the present application: reacting the ligand with a reducing agent in a buffer to obtain the reduced ligand.
- the step of removing the reducing agent is included.
- the removing the reducing agent comprises subjecting the reaction product to a desalting column and/or ultrafiltration.
- the reducing agent is selected from the group consisting of tris(2-carboxyethyl)phosphine hydrochloride (TCEP), beta-mercaptoethanol, beta-mercaptoethylamine hydrochloride, and dithiothreose Alcohol (DTT).
- TCEP tris(2-carboxyethyl)phosphine hydrochloride
- beta-mercaptoethanol beta-mercaptoethylamine hydrochloride
- DTT dithiothreose Alcohol
- the buffer is selected from the group consisting of potassium dihydrogen phosphate-sodium hydroxide (KH 2 PO 4 -NaOH)/sodium chloride (NaCl)/diethyltriaminepentaacetic acid (DTPA) Buffer, disodium hydrogen phosphate-citric acid/sodium chloride (NaCl)/diethyltriaminepentaacetic acid (DTPA), boric acid-borax/sodium chloride (NaCl)/diethyltriaminepentaacetic acid (DTPA) , histidine-sodium hydroxide/sodium chloride (NaCl)/diethyltriaminepentaacetic acid (DTPA) and PBS/diethyltriaminepentaacetic acid (DTPA).
- KH 2 PO 4 -NaOH potassium dihydrogen phosphate-sodium hydroxide
- DTPA diethyltriaminepentaacetic acid
- Buffer dis
- the organic solvent is selected from the group consisting of acetonitrile (ACN), dimethylformamide (DMF), dimethylacetamide (DMA) and dimethylsulfoxide (DMSO).
- ACN acetonitrile
- DMF dimethylformamide
- DMA dimethylacetamide
- DMSO dimethylsulfoxide
- the volume ratio of the organic solvent in the buffer solution and the organic solvent mixture does not exceed 30%.
- This application finds that the antibody-drug conjugates in this application, compared with traditional antibody-drug conjugates, due to the large hydrophobicity of ixatecan and belotecan drugs, the introduction of polysarcosine can The hydrophilicity of the conjugate is greatly increased, thereby making the obtained antibody-drug conjugate more stable and less prone to polymerization as a whole.
- the present application provides carbamate, which can undergo rapid 1,6-elimination after enzymatic cleavage to release the drug, and has better stability and biological activity in vitro and in vivo. Based on the above findings, the present application has been completed.
- Figure 1 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 1 of the present application
- Figure 2 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 2 of the present application
- Figure 3 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 2 of the present application
- Figure 4 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 3 of the present application
- Figure 5 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 4 of the present application
- Figure 6 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 4 of the present application
- Figure 7 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 5 of the present application
- Figure 8 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 5 of the present application
- Figure 9 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 6 of the present application.
- Figure 10 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 6 of the present application
- Figure 11 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 7 of the present application
- Figure 12 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 7 of the present application
- Figure 13 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 8 of the present application
- Figure 14 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 8 of the present application
- Figure 15 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 9 of the present application
- Figure 16 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 9 of the present application
- Figure 17 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 10 of the present application
- Figure 18 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 10 of the present application
- Figure 19 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 11 of the present application
- Figure 20 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 11 of the present application
- Figure 21 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 12 of the present application
- Figure 22 shows the hydrophobic interaction high performance liquid chromatogram (HIC-HPLC) of the antibody conjugate 12 of the present application
- Figure 23 shows the concentration change diagram of the accelerated stability experiment of some antibody conjugates of the present application.
- Figure 24 shows a graph showing the increase of aggregates in the accelerated stability experiment of some antibody conjugates of the present application.
- Figure 25 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 13 of the present application
- Figure 26 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 14 of the present application
- Figure 27 shows the size exclusion chromatography (SEC-HPLC) chromatogram of the antibody conjugate 15 of the present application
- Figure 28 shows a comparison chart of the efficacy results of some antibody conjugates of the present application in human lung squamous cell carcinoma NCI-H2170;
- Figure 29 is a graph showing the changes in the body weight of mice in the in vivo efficacy experiment of partial antibody conjugates of the present application in human lung squamous cell carcinoma cells NCI-H2170.
- the term "ligand” generally refers to a macromolecular compound capable of recognizing and binding to an antigen or receptor associated with a target cell.
- the role of the ligand can be to present the drug to the target cell population that binds to the ligand, including but not limited to protein hormones, lectins, growth factors, antibodies, or others that can bind to cells, receptors and/or antigens molecule.
- the ligand can be represented as Ab, and the ligand antigen forms a bond with the connecting unit through the heteroatom on the ligand, which can be an antibody or an antigen-binding fragment thereof, and the antibody can be selected from chimeric antibodies, human-derived antibody, fully human, or murine; the antibody may be a monoclonal antibody.
- the antibody may be an antibody or antigen-binding fragment thereof targeting a target selected from the group consisting of: HER2.
- alkyl generally refers to a residue derived from an alkane by removal of a hydrogen atom. Alkyl groups can be substituted or unsubstituted, substituted or unsubstituted.
- alkyl generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having a residue derived by removing a hydrogen atom from the same carbon atom or two different carbon atoms of the parent alkane, which may be a group containing 1 to A straight or branched chain group of 20 carbon atoms, eg 1 to 12 carbon atoms, eg, an alkane alkyl group containing 1 to 6 carbon atoms.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, and the like.
- Alkyl groups may be substituted or unsubstituted, substituted or non-substituted, for example when substituted, substituents may be substituted at any available point of attachment, and the substituents may be independently optionally selected from alkyl groups , alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy , heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and one or more substituents in oxo, such as hydrogen, protium, deuterium, tritium, halogen, -NO 2 , - CN, -OH,
- alkylene generally refers to a saturated straight or branched chain aliphatic hydrocarbon group having 2 hydrogen atoms derived from the same or two different carbon atoms of the parent alkane by removing two hydrogen atoms.
- residue which may be a straight or branched chain group containing 1 to 20 carbon atoms, for example, the term “methylene” may refer to a residue derived from a group of 1 carbon atom by removing two hydrogen atoms base.
- a methylene group may be substituted or unsubstituted, substituted or non-substituted; eg, an alkylene group containing from 1 to 12 carbon atoms, eg, an alkylene group containing from 1 to 6 carbon atoms.
- Non-limiting examples of alkylene groups include, but are not limited to, methylene ( -CH2- ), 1,1-ethylene (-CH( CH3 )-), 1,2-ethylene ( -CH2) CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene ( -CH2CH2CH2- ), 1,4 - Butylene ( -CH2CH2CH2CH2- ) and 1,5 - Butylene ( -CH2CH2CH2CH2CH2- ) Wait.
- Alkylene may be substituted or unsubstituted, substituted or non-substituted, for example, when substituted, substituents may be substituted at any available point of attachment, which may be independently optionally selected from alkanes group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy substituted by one or more substituents in the group, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo, such as hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH
- alkenyl generally refers to a straight or branched chain hydrocarbon group containing one or more double bonds.
- alkenyl groups include allyl, homoallyl, vinyl, crotyl, butenyl, pentenyl, hexenyl, and the like.
- C2-6 alkenyl groups having more than one double bond include butadienyl, pentadienyl, hexadienyl, and hexatrienyl and branched forms thereof.
- the position of the unsaturated bond (double bond) can be anywhere in the carbon chain.
- Alkenyl groups can be substituted or unsubstituted.
- alkenylene generally refers to residues having two hydrogen atoms removed from the carbon atoms of an olefin.
- alkenylene groups can be substituted or unsubstituted.
- alkynyl generally refers to unsaturated straight or branched chain alkynyl groups such as ethynyl, 1-propynyl, propargyl, butynyl, and the like. Alkynyl groups can be substituted or unsubstituted.
- alkynylene generally refers to residues having two hydrogen atoms removed from the carbon atoms of an alkyne.
- it can be ethynylene, propynylene, propargylene, butynylene and the like.
- Alkynylene groups can be substituted or unsubstituted.
- aryl generally refers to residues having an aromatic ring derived by removing one hydrogen atom.
- aromatic ring may refer to a 6- to 14-membered all-carbon monocyclic or fused polycyclic ring (ie, rings that share adjacent pairs of carbon atoms) having a conjugated pi-electron system, and may be 6 to 10 membered, such as benzene and Naphthalene.
- the aromatic ring can be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring linked to the parent structure is an aryl ring.
- Aryl may be substituted or unsubstituted, and when substituted, the substituent may be one or more of the following groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , and heterocycloalkylthio.
- Aryl groups can be substituted or unsubstituted.
- arylene generally refers to a residue having two hydrogen atoms removed from a carbon atom of an aromatic ring.
- phenylene and naphthylene may be mentioned.
- Arylene groups can be substituted or unsubstituted.
- heteroaryl generally refers to a residue having a hydrogen atom removed from a carbon atom of a heteroaromatic ring.
- heteromatic ring refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms may be selected from the group consisting of oxygen, sulfur and nitrogen.
- Heteroaryl can be 5 to 10 membered, 5 membered or 6 membered, such as furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazole Base et al.
- the heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring.
- Heteroaryl groups can be optionally substituted or unsubstituted, and when substituted, the substituents can be one or more of the following groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy group, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, ring Alkylthio, and heterocycloalkylthio. Heteroaryl groups can be substituted or unsubstituted.
- heteroarylene generally refers to a residue having two hydrogen atoms removed from a carbon atom of a heteroaromatic ring.
- it may be a furanylene group, a thienylene group, a pyridylene group, a pyrrolidine group, a pyrimidinylene group, a pyrazinylene group, an imidazolylylene group, a tetrazolium group, and the like.
- a heteroarylene group can be substituted or unsubstituted.
- alicyclic group generally refers to a residue having a hydrogen atom removed from the same carbon atom or a plurality of different carbon atoms of an alicyclic ring.
- cycloalkane generally refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon, the carbocyclic ring containing 3 to 20 carbon atoms, may contain 3 to 12 carbon atoms, may contain 3 to 10 carbon atoms, may Contains 3 to 8 carbon atoms.
- Non-limiting examples of alicyclic groups include cyclopropanyl, cyclobutanyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclopentyl Heptatrienyl, cyclooctyl, etc.; polycyclic carbocycles may include spiro, fused, and bridged carbocycles. Alicyclic groups can be substituted or unsubstituted.
- the term "carbocyclyl" generally refers to a residue derived from a carbon atom having a carbocyclic ring by removing one hydrogen atom.
- carbocycle generally refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon, the carbocycle contains 3 to 20 carbon atoms, may contain 3 to 12 carbon atoms, may contain 3 to 10 carbon atoms, may Contains 3 to 8 carbon atoms.
- Non-limiting examples of monocyclic carbocycles include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptatriene, cyclooctane etc.; polycyclic carbocycles may include spiro, fused and bridged carbocycles. Carbocyclyl groups can be substituted or unsubstituted. Alicyclic and carbocyclic may be used interchangeably in some cases.
- partially unsaturated generally refers to a cyclic structure containing at least one double or triple bond between the ring molecules.
- the term “partially unsaturated” encompasses cyclic structures with multiple unsaturations, but is not intended to include aromatic or heteroaromatic rings as defined herein.
- the term “unsaturated” means that the moiety has one or more degrees of unsaturation.
- alicyclic group generally refers to a residue having two hydrogen atoms removed from a carbon atom of an alicyclic ring.
- it can be cyclopropene, cyclobutane, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cyclohexadienylene, cycloheptane cycloheptatrienyl, cyclooctylene, etc.
- polycyclic carbocycles may include spiro, fused, and bridged carbocycles.
- Alicyclic groups can be substituted or unsubstituted.
- alicyclic heterocyclyl generally refers to stable non-aromatic 3- to 7-membered monocyclic carbocyclic structures, fused 7- to 10-membered bicyclic heterocyclic structures or bridged 6-membered -10-membered bicyclic heterocyclic structures, these cyclic structures can be either saturated or partially saturated, in addition to carbon atoms, these cyclic structures also contain one or more heteroatoms, wherein the heteroatoms can be selected from The following groups: oxygen, sulfur and nitrogen. For example, it contains 1-4 heteroatoms as defined above.
- nitrogen when used to refer to an atom on an alicyclic ring structure may include nitrogen that has undergone a substitution reaction.
- a heteroalicyclic group may include "heterocycloalkyl", which may refer to a stable non-aromatic 3- to 7-membered monocycloalkane structure, a fused 7- to 10-membered bicyclic heterocyclic structure or Bridged 6- to 10-membered bicyclic heterocyclic structures containing, in addition to carbon atoms, one or more heteroatoms, wherein the heteroatoms may be selected from the group consisting of oxygen, sulfur and nitrogen. For example, it contains 1-4 heteroatoms as defined above.
- Heterocycloalkyl can be substituted or unsubstituted.
- Alicyclic groups may be substituted or unsubstituted.
- alicyclic heterocyclyl generally refers to a residue having two hydrogen atoms removed from a carbon atom of an alicyclic ring. Aliphatic heterocyclyl groups can be substituted or unsubstituted.
- a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may, but need not, be present, and the specification may include both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group. situation.
- substituted generally means that one or more hydrogen atoms in a group, eg up to 5, eg 1 to 3 hydrogen atoms, independently of one another, are substituted by the corresponding number of substituents.
- Substituents are only in their possible chemical positions, and those skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort.
- amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
- alkyl alkenyl
- cycloalkyl alkyl
- C 3 alkyl C 3 -C 7 cycloalkoxy, C 1 -C 4 alkylcarbonylamino, etc.
- C followed by a subscript number indicates the number of atoms present in the group number of carbon atoms.
- C3 alkyl refers to an alkyl group having three carbon atoms (eg, n-propyl, isopropyl); in C1-10 , the members of the group can have any number falling within the range of 1-10 of carbon atoms.
- One or more hydrogen atoms in the group are substituted by the corresponding number of substituents.
- Substituents are only in their possible chemical positions, and those skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort.
- amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
- the term "compound” generally refers to a substance having two or more different elements.
- the compound of the present application may be an organic compound.
- the compound of the present application may be a compound with a molecular weight of 500 or less, a compound with a molecular weight of 1,000 or less, or a compound with a molecular weight of 1,000 or more, or a compound of 10,000 or more and 100,000 or more. compound.
- a compound may also refer to a compound connected by chemical bonds, for example, it may be a compound in which one or more molecules with a molecular weight below 1000 are connected with a biological macromolecule by chemical bonds, and the biological macromolecule may be a high polysaccharide, a protein , nucleic acids, peptides, etc.
- the compounds of the present application may include compounds in which proteins are linked to one or more molecules with a molecular weight of less than 1000; A compound with less than 100,000 molecules linked together.
- the term "about” generally refers to a range of 0.5%-10% above or below the specified value, such as 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%.
- the compounds of the present application include tautomers, mesomers, racemates, enantiomers, and/or diastereomers of the compounds.
- the term “diastereomer” generally refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers can have different physical properties, eg, melting points, boiling points, spectral properties, and reactivities.
- the terms “tautomer” or “tautomeric form” are used interchangeably and generally refer to structural isomers of different energies that can be interconverted through a low energy barrier.
- protontautomers also known as prototropic tautomers
- prototropic tautomers include interconversions by migration of protons, such as keto-enol isomerization and imine-ene Amine isomerization.
- Valence tautomers include interconversions by recombination of some of the bonding electrons.
- mesome generally refers to atoms that contain asymmetry in the molecule, but have a symmetry factor such that the total optical rotation in the molecule is zero.
- racemate or “racemic mixture” refers to a composition consisting of two enantiomeric species in equimolar amounts.
- certain atoms of the compounds of the present application may occur in more than one isotopic form.
- hydrogen may exist as protium ( 1 H), deuterium ( 2 H), and tritium ( 3 H), and carbon may exist naturally in three different isotopes ( 12 C, 13 C, and 14 C).
- isotopes that can be incorporated into the compounds of the present application also include, but are not limited to, 15 N, 18 O, 17 O, 18 F, 32 P, 33 P, 129 I, 131 I, 123 I, 124 I, 125 I, or the like of isotopes.
- the compounds of the present application may be enriched in one or more of these isotopes relative to their natural abundance.
- Such isotopically enriched compounds can be used for a variety of purposes, as known to those skilled in the art.
- substitution with heavy isotopes such as deuterium ( 2 H) may offer certain therapeutic advantages, which may be due to greater metabolic stability.
- the natural abundance of deuterium ( 2 H) is about 0.015%. Therefore, for every 6,500 hydrogen atoms in nature, there is one deuterium atom. Accordingly, the deuterium-containing compounds of the present application have a deuterium abundance greater than 0.015% at one or more positions (as the case may be).
- structures described herein may also include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, except that the hydrogen atom is replaced by deuterium or tritium, or the carbon atom is replaced by carbon 13 or carbon 14, the compounds whose structure is consistent with the present application are all within the scope of the present application.
- the term "pharmaceutical composition” generally refers to a mixture containing one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other Such as physiological/pharmaceutically acceptable carriers and excipients.
- the pharmaceutical composition can facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- the preparation of conventional pharmaceutical compositions can be found in the techniques commonly used in the art.
- the term "pharmaceutically acceptable salt” or “pharmaceutically acceptable salt” generally refers to a salt of a compound or ligand-drug conjugate of the present application, or a salt of a compound described in the present application, Such salts can be safe and/or effective when used in mammals, and can have due biological activity, and the antibody-antibody drug conjugate compounds of the present application can form salts with acids, and the pharmaceutically acceptable salts are salts.
- Non-limiting examples include: hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, pear Acid, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, mesylate, ethyl acetate Sulfonate, benzenesulfonate, or p-toluenesulfonate.
- conjugate generally refers to a compound of the present application prepared by one or more chemical reactions, or by one such as a bridge, spacer, or linking moiety, etc. or multiple connecting structures are connected to each other.
- a pharmaceutically acceptable carrier generally refers to a carrier for administration of therapeutic agents, such as antibodies or polypeptides, genes and other therapeutic agents.
- the term refers to any pharmaceutical carrier that itself does not induce the production of antibodies detrimental to the individual receiving the composition and can be administered without undue toxicity.
- a pharmaceutically acceptable carrier can be distinguished from a nucleic acid vector used in genetic engineering to contain a gene of interest. Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, lipid aggregates, and inactivated viral particles. Those skilled in the art are familiar with these vectors.
- Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances such as wetting or emulsifying agents, pH buffering substances and the like can also be present in these carriers.
- Trop2 generally refer to a single-pass transmembrane type I cell membrane protein.
- the term “Trop2” may also encompass homologues, variants and isoforms of Trop 2, including splice isoforms.
- the term “Trop” also includes proteins having one or more sequences of Trop 2 homologues, variants and isoforms, as well as fragments of such sequences, so long as the variant protein (including isoforms).
- Trop2 can be human Trop2.
- Uniprot Accession No. P09758 provides a description of Trop2 and sequences.
- HER2 generally refers to human epidermal growth factor receptor 2 (HER2).
- HER2 refers to any native HER2 from any human source.
- the term also encompasses "full-length” and unprocessed HER2 as well as any form of HER2 derived from processing in a cell (eg, the mature protein).
- the term also encompasses naturally occurring variants and isoforms of HER2, such as splice variants or allelic variants.
- Uniprot Accession No. P04626 provides a description of HER2 and sequences.
- Nectin-4" generally refers to adhesion molecule 4.
- Nectin-4" refers to any native Nectin-4 from any human source.
- the term also encompasses "full-length” and unprocessed Nectin-4 as well as any form of Nectin-4 derived from processing in a cell (eg, mature protein).
- the term also encompasses naturally occurring variants and isoforms of Nectin-4, such as splice variants or allelic variants.
- Uniprot Accession No. Q96NY8 provides a description of Nectin-4 and sequences.
- chimeric antibody generally refers to an antibody in which the variable region of a murine antibody is fused with the constant region of a human antibody, which can alleviate the immune response induced by the murine antibody.
- a hybridoma that secretes a mouse-specific monoclonal antibody can be established, and then the variable region gene can be cloned from the mouse hybridoma cell, and the constant region gene of the human antibody can be cloned according to the needs.
- the human constant region gene is connected into a chimeric gene and inserted into an expression vector, and the chimeric antibody molecule can be expressed in a eukaryotic system or a prokaryotic system.
- humanized antibody also known as CDR-grafted antibody
- CDR-grafted antibody generally refers to the grafting of murine CDR sequences into the framework of human antibody variable regions, i.e. different Types of human germline antibody framework sequences produced in antibodies.
- the heterologous reaction induced by chimeric antibodies can be overcome because they carry a large amount of murine protein components.
- framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences.
- the germline DNA sequences of the human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database.
- monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully human monoclonal antibodies.
- the antibodies or ligands described herein may be fully human monoclonal antibodies.
- Related technologies for the preparation of fully human antibodies include: human hybridoma technology, EBV transformation of B lymphocytes, phage display technology, transgenic mouse antibody preparation technology, and single B cell antibody preparation technology.
- CDR generally refers to one of the six hypervariable regions within the variable domain of an antibody that primarily contribute to antigen binding.
- One of the most commonly used definitions of the 6 CDRs is provided by Kabat E.A. et al., Chothia et al. and MacCallum et al.
- the Kabat definition of CDRs can be applied to CDR1, CDR2 and CDR3 (CDR L1, CDR L2, CDR L3 or L1, L2, L3) of the light chain variable domains, as well as the heavy chain variable domains of CDR1, CDR2 and CDR3 (CDR H1, CDR H2, CDR H3 or H1, H2, H3).
- group capable of coupling with a thiol group generally means that the compound A has a thiol group, the compound B has a group capable of coupling with a thiol group, and the compound B has a group capable of coupling with a thiol group through a group capable of coupling with a thiol group.
- the group reacts with the sulfhydryl group of compound A, which can realize the connection between compound A and compound B.
- linker usually refers to a chemical structural fragment or bond with one end connected to one group and the other end connected to another group. It can also be connected to other linkers and then to drugs and/or ligands. connected.
- the direct or indirect linking of the ligand may refer to that the group is directly linked to the ligand through a covalent bond, or may be linked to the ligand through a linker.
- the linker can be the structure shown by Q 1 described in this application.
- chemical fragments comprising acid-labile linker structures (eg, hydrazones), protease-sensitive (eg, peptidase-sensitive) linker structures, photolabile linker structures, dimethyl linker structures, or disulfide-containing linker structures may be used or bond as a linker.
- acid-labile linker structures eg, hydrazones
- protease-sensitive linker structures eg, peptidase-sensitive linker structures
- photolabile linker structures eg, dimethyl linker structures
- disulfide-containing linker structures may be used or bond as a linker.
- linking group generally refers to a group that has the ability to attach to another group.
- the linking of the compound with another group can be achieved through a coupling reaction between the linking group and another group.
- a maleimide group can serve as the linking group.
- drug unit generally refers to a chemical moiety that directly or indirectly conjugates an antibody or antigen-binding fragment to form an immunoconjugate.
- a drug unit includes, but is not limited to, compounds described herein with anti-tumor activity.
- the drug unit includes a topoisomerase inhibitor.
- the term "compound with antitumor activity” generally refers to a compound having the ability to reduce the proliferation rate, viability or metastatic activity of tumor cells.
- anti-tumor activity may be manifested by a reduction in the growth rate of abnormal cells or by stabilization or shrinkage of tumor size during treatment, or by longer survival due to treatment compared to a control in the absence of treatment.
- Antitumor activity can be assessed using recognized in vitro or in vivo tumor models, such as xenograft models.
- the biologically active molecule in the conjugate is a compound with specific anti-tumor activity, for example, a radioisotope, such as At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , or radioisotopes of Lu; metal complexes, such as metal platinum complexes (such as oxaliplatin) or metal gold complexes; glycopeptide antibiotics, such as bleomycin or pingyangmycin; topoisomerase inhibitors; drugs that interfere with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladrix Drugs acting on structural proteins, such as tubulin inhibitors (such as vinca alkaloids, vincristine, vinblastine, paclitaxel
- topoisomerase inhibitor generally refers to compounds or derivatives thereof that include topoisomerase I inhibitors and topoisomerase II inhibitors.
- topoisomerase I inhibitors include, but are not limited to, camptothecin and its analogs; topoisomerase II inhibitors (such as actinomycin D, doxorubicin, doxorubicin, docarmycin, daunorubicin, mitoxantrone, podophyllotoxin or etoposide, etc.).
- a topoisomerase may refer to an enzyme that corrects the number of concatenated chains of DNA by cleaving phosphodiester bonds in one or both strands of DNA, followed by rewinding and sealing.
- camptothecin analog generally refers to compounds that are structurally similar to or derived from camptothecin.
- structure of camptothecin can be described in CAS Accession No. 7689-03-4.
- a camptothecin analog may refer to ixatecan (Exatecan, CAS Accession No. 171335-80-1) or Belotecan (Belotecan, CAS Accession No. 256411-32-2).
- non-camptothecin-type topoisomerase I inhibitors generally refers to indolecarbazoles, indenoisoquinolinones, triphenanthridines, and dibenzonaphthyridinones with topoisomerases I heterocyclic molecules with inhibitory activity mainly refer to Genz-644282 (CAS accession number 529488-28-6).
- the term "expression-related" disease of a target generally means that the occurrence and/or progression of the disease is associated with the expression level of the target.
- the expression level of a target in cells from a disease area such as within a particular tissue or organ of a patient, is increased, ie, highly expressed, relative to the expression level of normal cells from the tissue or organ.
- the expression level of a certain target in cells from a disease area such as a particular tissue or organ of a patient, is reduced, ie, underexpressed, relative to the expression level of normal cells from the tissue or organ.
- cells from a disease area such as within a particular tissue or organ of a patient, express a certain target, ie, are positive.
- cells from a disease area such as a particular tissue or organ of a patient, do not express a certain target, ie, are negative.
- target expression can be characterized by standard assays known in the art.
- the term "effective amount” generally refers to the amount of a therapeutic agent that treats, ameliorates, or prevents a target disease or condition, or an amount that exhibits a measurable therapeutic or prophylactic effect.
- the precise effective amount for a subject depends on the size and health of the subject, the nature and extent of the disorder, and the therapeutic agent and/or combination of therapeutic agents selected for administration. Therefore, it is useless to prespecify the exact effective amount. However, for a given situation, routine experimentation can be used to determine the effective amount, as is the judgment of the clinician.
- each chiral carbon atom can optionally be in the R configuration or the S configuration, or a mixture of the R configuration and the S configuration.
- the term "compound of the present application” refers to a compound of the present application.
- the term also includes various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compounds of the present application.
- the tradename is intended to include the tradename product formulation, its corresponding generic drug, and the active pharmaceutical ingredient of the tradename product.
- antibody is used in its broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (eg, bispecific antibodies), and antibody fragments, so long as they are exhibit the desired biological activity.
- Antibodies can be murine, human, humanized, chimeric, or derived from other species.
- Antibodies are proteins produced by the immune system capable of recognizing and binding specific antigens.
- Target antigens generally have a large number of binding sites, also referred to as epitopes, recognized by the CDRs of various antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, an antigen can have more than one corresponding antibody.
- Antibodies include full-length immunoglobulin molecules or immunologically active portions of full-length immunoglobulin molecules, i.e., molecules that contain an antigen or portion thereof that specifically binds a target of interest, including, but not limited to, cancer cells or Cells with autoimmune antibodies associated with autoimmune diseases.
- the immunoglobulins described herein can be of any class (eg, IgG, IgE, IgM, IgD, and IgA), class (eg, IgGl, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules. Immunoglobulins can be derived from any species.
- the immunoglobulin is derived from human, murine or rabbit.
- An "antibody fragment” may comprise a portion of a full-length antibody, typically its antigen-binding or variable region.
- antibody fragments include: Fab, Fab', F(ab')2 and Fv fragments; diabodies; linear antibodies; minibodies; Fab expression library prepared fragments; anti-idiotypic (anti-Id) antibodies ; CDRs (complementarity determining regions); and any of the above epitope-binding fragments that immunospecifically bind to cancer cell antigens, viral antigens, or microbial antigens; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
- the antibody constituting the antibody-drug conjugate in the present application can maintain the antigen-binding ability of its original wild state.
- the antibodies of the present application can, for example, specifically bind to an antigen.
- Antigens involved include, for example, tumor-associated antigens (TAAs), cell surface receptor proteins and other cell surface molecules, regulators of cell survival, regulators of cell proliferation, molecules associated with tissue growth and differentiation (as known or predicted) functional), lymphokines, cytokines, molecules involved in the regulation of the cell cycle, molecules involved in angiogenesis, and molecules involved in angiogenesis (eg known antibodies bind antigens can be one or a subset of the above categories , while other subsets contain other molecules/antigens with specific properties (compared to the target antigen).
- TAAs tumor-associated antigens
- cell surface receptor proteins and other cell surface molecules regulators of cell survival, regulators of cell proliferation, molecules associated with tissue growth and differentiation (as known or predicted) functional
- lymphokines cytokines
- Antibodies used in antibody drug conjugates include, but are not limited to, targeting cell surface receptors and tumor-associated Antibodies to antigens.
- tumor-associated antigens are well known in the industry and can be prepared by well-known antibody preparation methods and information in the industry. These targets can be specifically expressed on the surface of one or more cancer cells, while in a or a variety of non-cancerous cell surfaces expressed little or no.
- tumor-associated polypeptides can be more overexpressed on the surface of cancer cells relative to the surface of non-cancer cells.
- enrozumab generally refers to an antibody that targets Nectin-4.
- Enfortumab can be described in WO2017042210A1.
- ennozumab may refer to any antibody or antigen-binding fragment comprising the heavy chain variable region CDR1-3 and light chain variable region CDR1-3 of enrozumab.
- ennozumab may refer to any antibody or antigen-binding fragment comprising the heavy chain variable region and light chain variable region of enrozumab.
- Pertuzumab generally refers to an antibody that targets HER2.
- Pertuzumab can be described in WO2014172371A2.
- Pertuzumab may refer to any antibody or antigen-binding fragment comprising the heavy chain variable region CDR1-3 and the light chain variable region CDR1-3 of Pertuzumab.
- Pertuzumab can refer to any antibody or antigen-binding fragment comprising the variable region of the heavy chain and the variable region of the light chain of Pertuzumab.
- trastuzumab generally refers to an antibody that targets HER2.
- Trastuzumab can be described in US20060275305A1.
- trastuzumab may refer to any antibody or antigen-binding fragment comprising the heavy chain variable region CDR1-3 and light chain variable region CDR1-3 of trastuzumab.
- trastuzumab may refer to any antibody or antigen-binding fragment comprising the heavy and light chain variable regions of trastuzumab.
- certolizumab generally refers to an antibody that targets TROP2.
- Sacituzumab hRS7
- certolizumab may refer to any antibody or antigen-binding fragment comprising the heavy chain variable region CDR1-3 and light chain variable region CDR1-3 of certolizumab.
- certolizumab may refer to any antibody or antigen-binding fragment comprising the heavy and light chain variable regions of certolizumab.
- Patritumab generally refers to an antibody that targets HER3.
- Patritumab can be described in CN102174105B.
- Patritumab monoclonal antibody may refer to any antibody or antigen-binding fragment comprising the heavy chain variable region CDR1-3 and light chain variable region CDR1-3 of Patritumab.
- Patritumab may refer to any antibody or antigen-binding fragment comprising the variable region of the heavy chain and the variable region of the light chain of Patritumab.
- the term "antibody H01L02" generally refers to an antibody targeting CDH6.
- the monoclonal antibody H01L02 can be described in WO2018212136, US20200171163A1.
- the H01L02 mAb can be the mAb used by the drug DS6000.
- the H01L02 monoclonal antibody may refer to any antibody or antigen-binding fragment comprising the heavy chain variable region CDR1-3 and the light chain variable region CDR1-3 of the H01L02 monoclonal antibody.
- the H01L02 mAb can refer to any antibody or antigen-binding fragment comprising the heavy chain variable region and the light chain variable region of the H01L02 mAb.
- polypeptide residue generally refers to a residue comprising one or more amino acid residues linked together.
- one or more amino acids in a polypeptide residue may be optionally substituted.
- the polypeptide residues of the present application may be selected from the group consisting of phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val) -Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine ( Val-Lys), Alanine-Alanine-Alanine (Ala-Ala-Ala), Alanine-Alanine-Asparagine (Ala-Ala-Asn), and Glycine-Glycine-Phenylalanine Acid-glycine (Gly-Gly-Phe-Gly).
- polyethylene glycol generally refers to a residue comprising one or more ethylene glycol residues linked together.
- a polyethylene glycol group may comprise - ( CH2CH2O ) p- , where p is a number of at least one.
- polyethylene glycol groups in this application may be optionally substituted.
- glycol group generally refers to a polyethylene glycol group.
- glycol groups in this application may be optionally substituted.
- a number preceding a glycol group may indicate the number of ethylene glycol units of a glycol group, eg, a diethylene glycol group may refer to the polymerized residue of two glycols.
- polysarcosine residue generally refers to a residue comprising one or more sarcosine residues linked together.
- a polysarcosine residue may comprise -(COCH2N( CH3 ) ) q- , where q is a number of at least one.
- polysarcosine residues in the present application may be optionally substituted.
- a structure containing polysarcosine residues can be where n2 is a number from 4 to 18.
- sodium dodecyl sulfate polyacrylamide gel electrophoresis generally refers to an analytical characterization technique for substances.
- sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
- hydrophobic chromatography generally refers to an analytical technique based on differences in the hydrophobicity of substances.
- liquid phase mass spectrometry generally refers to an analytical method for identifying constituents of matter.
- liquid chromatography-mass spectrometry can analyze the molecular weight of the substance to be tested by liquid chromatography-mass spectrometry.
- tumor generally refers to any new pathological tissue proliferation.
- angiogenesis is part of the tumor profile.
- Tumors can be benign or malignant.
- the term “tumor” is generally used to refer to benign or malignant tumors, while the term “cancer” is generally used to refer to malignant tumors, which may be metastatic or non-metastatic.
- Tumors diagnosable by the methods of the present application are selected from the group consisting of breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, Prostate cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal colon, gastric cancer, glial tumor and mesothelioma.
- these tissues can be isolated from readily available sources by methods well known to those skilled in the art.
- the application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable compound thereof.
- An acceptable salt, prodrug or solvate, wherein the compound may comprise the structure of formula (C-Trop-2):
- Q 1 may contain a linker
- L 1a can be selected from the following group: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted idene cyclyl, optionally substituted alicyclic heterocyclyl, optionally substituted arylene, and optionally substituted heteroarylene;
- L2 may comprise optionally substituted polypeptide residues
- L 3 may contain an optionally substituted spacer group, for example, the spacer group of the present application may be self-degradable.
- the spacer groups of the present application may comprise optionally substituted or optionally substituted
- L2 and/or L3 may comprise optionally substituted polysarcosine residues
- T may contain drug units
- Ab can be a ligand capable of binding Trop-2, and m can be a number from 1-8.
- the present application also provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a mixture thereof A pharmaceutically acceptable salt, prodrug or solvate, wherein the compound may comprise a structure represented by the formula (C-Trop-2-M):
- Q 1 may contain a linker
- L 1a can be selected from the following group: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted idene cyclyl, optionally substituted alicyclic heterocyclyl, optionally substituted arylene, and optionally substituted heteroarylene;
- L2 may comprise optionally substituted polypeptide residues
- L 3 may contain an optionally substituted spacer group, for example, the spacer group of the present application may be self-degradable.
- the spacer groups of the present application may comprise optionally substituted or optionally substituted
- L 2 and/or L 3 may comprise optionally substituted structural unit-X
- T may contain drug units
- Ab can be a ligand capable of binding Trop-2, and m can be a number from 1-8.
- L is selected from the group of: optionally substituted and optionally substituted
- the benzene ring of L 3 may be substituted by the optionally substituted structural unit -X.
- the structural unit -X can be selected from the group of: optionally substituted wherein X 1 is selected from the group consisting of carbonyl, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and Linear-cyclic heteroalkyl groups containing 1-8 atoms containing 1-3 atoms selected from N, O or S ; wherein X is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkane containing 1-8 atoms group, the heteroalkyl group contains 1-3 atoms selected from N, O or S; wherein X 3 is
- the benzene ring of L 3 may be substituted by the optionally substituted structural unit -X.
- the building block -X may contain an optionally substituted wherein X 1 is selected from the group consisting of C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and containing 1 -8-atom straight-chain-cyclic heteroalkyl, said heteroalkyl containing 1-3 atoms selected from N, O or S, said C 1 -C 8 alkyl, C 1 -C 8 Alkoxy, C1 - C6cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkyl containing 1-8 atoms are each independently optionally selected from Substituted with one or more substituents of deuterated, halogen, cyano, nitro, amino, alkyl, carboxyl, al
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C-Trop-2-M2):
- L can contain an optionally substituted alkylene group, an optionally substituted polyethylene glycol group and an optionally substituted alicyclic group;
- R 1 can be an optionally substituted isopropyl group or an optionally substituted benzyl group ;
- R 2 can be optionally substituted methyl, optionally substituted or optionally substituted
- R 3 can be hydrogen or R 5 ; wherein R 5 can be optionally substituted T may comprise ixatecan (Exatecan, CAS accession number 171335-80-1) and/or belonotecan (Belotecan, CAS accession number 256411-32-2) and/or Genz-644282 (CAS accession number 529488- 28-6).
- Q 1 may comprise a linker coupled with a thiol group.
- Q 1 can be selected from the group of: optionally substituted optionally substituted optionally substituted and optionally substituted
- L 1a may be selected from the group consisting of optionally substituted C 1 -C 7 alkylene, optionally substituted diethylene glycol to octaethylene glycol, optionally substituted C 3 -C 6 alkylene Alicyclic, optionally substituted arylene, and optionally substituted heteroarylene.
- L 1a may be selected from the group consisting of optionally substituted methylene, optionally substituted ethylene, optionally substituted propylene, optionally substituted butylene, optionally substituted pentylene , optionally substituted diethylene glycol, optionally substituted tetraethylene glycol, optionally substituted hexaethylene glycol, optionally substituted octaethylene glycol, and optionally substituted cyclohexylene.
- L 1a can be selected from the group consisting of optionally substituted methylene, optionally substituted ethylene, optionally substituted propylene, optionally substituted butylene, and optionally substituted pentylene base.
- L 1a can be selected from the group of: optionally substituted diethylene glycol, optionally substituted triethylene glycol, optionally substituted tetraethylene glycol, optionally substituted pentaethylene glycol, optionally substituted Substituted hexaethylene glycol, optionally substituted heptaethylene glycol, and optionally substituted octaethylene glycol.
- L 1a may be selected from the group consisting of optionally substituted cyclopropylene, optionally substituted cyclobutylene, and optionally substituted cyclohexylene.
- L2 may comprise optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of phenylalanine, isoleucine, leucine, tryptophan, valine, methionine , tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartate acid and glycine.
- amino acids selected from the group consisting of phenylalanine, isoleucine, leucine, tryptophan, valine, methionine , tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartate acid and glycine.
- L 2 may comprise optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartate acid, asparagine and lysine.
- L 2 may comprise an optionally substituted polypeptide residue selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine Acid-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine Amino-Lysine (Val-Lys), Alanine-Alanine-Alanine (Ala-Ala-Ala), Alanine-Alanine-Asparagine (Ala-Ala-Asn) and Glycine-Glycine-Phenylalanine-Glycine (Gly-Gly-Phe-Gly).
- Phe-Lys phenylalanine-lysine
- Val-Ala valine-alanine
- Val-Cit valine Acid-citrulline
- Glu-Val-Ala glutamic acid-
- L 2 may comprise an optionally substituted polypeptide residue selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine Acid-citrulline (Val-Cit) and valine-lysine (Val-Lys).
- L2 comprises a lysine residue
- the lysine residue can be substituted by a structure R1 comprising a polysarcosine residue.
- any H contained in L 2 may be substituted by R 1 .
- the R 1 can be optionally substituted wherein n1 is a number from 4 to 18, and R is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, and C 1 -C 6 alkoxy.
- n1 can be 4 to 18, 8 to 18, 4 to 12, or 8 to 12.
- n1 can be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18.
- L is selected from the group of: optionally substituted and optionally substituted
- the benzene ring of L3 can be substituted with a structure R2 comprising a polysarcosine residue.
- any H contained in the benzene ring of L 3 may be substituted by R 2 .
- the structural unit -X- is selected from the group consisting of: optionally substituted wherein X 1 is selected from the group consisting of carbonyl, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and Linear-cyclic heteroalkyl groups containing 1-8 atoms containing 1-3 atoms selected from N, O or S ; wherein X is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkane containing 1-8 atoms group, the heteroalkyl group contains 1-3 atoms selected from N, O or S;
- the benzene ring of L 3 is connected to the optionally substituted polysarcosine residue through a structural unit -X-, which is selected from, but is not limited to: wherein X 1 is selected from the group consisting of C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and containing 1 -8-atom straight-chain-cyclic heteroalkyl, said heteroalkyl containing 1-3 atoms selected from N, O or S, said C 1 -C 8 alkyl, C 1 -C 8 Alkoxy, C1 - C6cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkyl containing 1-8 atoms are each independently optionally selected from Substituted with one or more substituents of deuterated, halogen, cyano, nitro, amino, alkyl, carboxyl,
- the optionally substituted polysarcosine residue comprises wherein n2 is a number from 4 to 18, and R is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, and C 1 -C 6 alkoxy.
- the structural unit -X- is selected from the group consisting of optionally substituted wherein X 1 is selected from the group consisting of carbonyl, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and Linear-cyclic heteroalkyl groups containing 1-8 atoms containing 1-3 atoms selected from N, O or S ; wherein X is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkane containing 1-8 atoms group, the heteroalkyl group contains 1-3 atoms selected from N, O or S; wherein X 3 is a covalent bond or is selected from the following group: hydrogen, C 1 -C 8 alkyl, C 1 -
- the optionally substituted polysarcosine residue comprises wherein n2 is a number from 4 to 18, and R is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, and C 1 -C 6 alkoxy.
- the structural unit -X- is selected from the group consisting of optionally substituted wherein X 1 is selected from the group consisting of carbonyl, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and Linear-cyclic heteroalkyl groups containing 1-8 atoms containing 1-3 atoms selected from N, O or S ; wherein X is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkane containing 1-8 atoms group, the heteroalkyl group contains 1-3 atoms selected from N, O or S; wherein X 3 is a covalent bond or is selected from the following group: hydrogen, C 1 -C 8 alkyl, C 1 -
- n2 can be 4 to 18, 8 to 18, 4 to 12, or 8 to 12.
- n2 can be 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18.
- T may comprise a compound having antitumor activity.
- T can comprise a topoisomerase inhibitor
- T can include camptothecin-based and non-camptothecin-based topoisomerase I inhibitors.
- T may comprise ixatecan (Exatecan, CAS accession number 171335-80-1) and/or belotecan (Belotecan, CAS accession number 256411-32-2) and/or Genz-644282 (CAS accession number 256411-32-2) Accession No. 529488-28-6).
- T can be selected from the following group:
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C-Trop-2):
- Q 1 may comprise a linker coupled with a thiol group
- L2 may comprise optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, aspartic acid amide and lysine,
- L 3 may contain optionally substituted
- L 2 may comprise a polysarcosine residue
- T may contain a topoisomerase inhibitor.
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C-Trop-2):
- Q 1 may comprise a linker coupled with a thiol group
- L2 may comprise optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, aspartic acid amide and lysine,
- L 3 may contain optionally substituted
- L3 may comprise a polysarcosine residue
- T may contain a topoisomerase inhibitor.
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C-Trop-2):
- Q 1 may contain optionally substituted
- L 2 may comprise a structure selected from the group consisting of phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit) and valine-lysine (Val-Lys),
- L 3 may contain optionally substituted
- L2 may comprise a lysine residue, and the lysine residue may be optionally substituted Substitution, where n1 is a number from 4 to 18,
- T may comprise ixatecan (Exatecan, CAS accession number 171335-80-1) and/or belonotecan (Belotecan, CAS accession number 256411-32-2) and/or Genz-644282 (CAS accession number 529488- 28-6).
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C-Trop-2):
- Q 1 can be selected from the following group: optionally substituted optionally substituted optionally substituted and optionally substituted
- L 2 may comprise a structure selected from the group consisting of phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit) and valine-lysine (Val-Lys),
- L 3 may contain optionally substituted
- L can be optionally substituted Substitution, wherein L can be optionally substituted Substitution, wherein n2 is a number from 4 to 18,
- T may comprise ixatecan (Exatecan, CAS accession number 171335-80-1) and/or belonotecan (Belotecan, CAS accession number 256411-32-2) and/or Genz-644282 (CAS accession number 529488- 28-6).
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C2-Trop-2):
- L can contain an optionally substituted alkylene group, an optionally substituted polyethylene glycol group and an optionally substituted alicyclic group;
- R 1 can be an optionally substituted isopropyl group or an optionally substituted benzyl group ;
- R 2 can be optionally substituted methyl, optionally substituted or optionally substituted R 3 can be hydrogen or optionally substituted methyl;
- R 2 can be optionally substituted Substitute, where n1 is a number from 4 to 18, and T may comprise ixatecan (Exatecan, CAS Accession No. 171335-80-1) and/or Belotecan (Belotecan, CAS Accession No. 256411-32-2) and /or Genz-644282 (CAS Accession No. 529488-28-6).
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C2-Trop-2):
- L can contain an optionally substituted alkylene group, an optionally substituted polyethylene glycol group and an optionally substituted alicyclic group;
- R 1 can be an optionally substituted isopropyl group or an optionally substituted benzyl group ;
- R 2 can be optionally substituted methyl, optionally substituted or optionally substituted R 3 can be hydrogen or optionally substituted methyl;
- R 2 can be optionally substituted Substitute, where n2 is a number from 4 to 18, and T may comprise ixatecan (Exatecan, CAS Accession No. 171335-80-1) and/or Belotecan (Belotecan, CAS Accession No. 256411-32-2) and /or Genz-644282 (CAS Accession No. 529488-28-6).
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C2-Trop-2):
- L can contain an optionally substituted alkylene group, an optionally substituted polyethylene glycol group and an optionally substituted alicyclic group;
- R 1 can be an optionally substituted isopropyl group or an optionally substituted benzyl group ;
- R 2 can be optionally substituted R 3 can be hydrogen or optionally substituted methyl;
- R 4 can be optionally substituted where n1 is a number from 4 to 18, and T may contain ixatecan (Exatecan, CAS accession number 171335-80-1) and/or belotecan (Belotecan, CAS accession number 256411-32-2) and/or Genz-644282 (CAS Accession No. 529488-28-6).
- the present application provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Accepted salts, prodrugs or solvates, wherein the compound may comprise the structure of formula (C2-Trop-2):
- L can contain an optionally substituted alkylene group, an optionally substituted polyethylene glycol group and an optionally substituted alicyclic group;
- R 1 can be an optionally substituted isopropyl group or an optionally substituted benzyl group ;
- R 2 can be optionally substituted methyl, optionally substituted or optionally substituted
- R 3 can be hydrogen or R 5 ; wherein R 5 can be optionally substituted where n2 is a number from 4 to 18, and T may comprise ixatecan (Exatecan, CAS accession number 171335-80-1) and/or belotecan (Belotecan, CAS accession number 256411-32-2) and/or Genz-644282 (CAS Accession No. 529488-28-6).
- the Ab can comprise an anti-Trop-2 antibody or antigen-binding fragment thereof.
- the antibody may be selected from the group consisting of murine antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies.
- the antibody may comprise a monoclonal antibody.
- the antibody may comprise a bispecific antibody.
- the antigen-binding fragment may be selected from the group consisting of Fab, Fab', Fv fragments, F(ab') 2 , F(ab) 2 , scFv, di-scFv, VHH and dAb.
- the heavy chains HCDR1, HCDR2 and HCDR3 and light chains LCDR1, LCDR2 and LCDR3 of the Ab comprise heavy chains HCDR1, HCDR2 and HCDR3 and light chains LCDR1, LCDR2 and LCDR3, respectively, of an anti-Trop-2 antibody.
- the heavy chain variable region VH and light chain variable region VL of the Ab comprise the heavy chain variable region VH and light chain variable region VL, respectively, of an anti-Trop-2 antibody.
- the heavy and light chains of the Ab comprise the heavy and light chains, respectively, of an anti-Trop-2 antibody.
- the Ab can comprise certolizumab (Sacituzumab, hRS7).
- m can be determined by a method selected from the group consisting of hydrophobic chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, and liquid phase mass spectrometry.
- m is the average value of the molar ratio of drug molecules to monoclonal antibody molecules in the antibody-conjugated drug obtained by coupling a single monoclonal antibody molecule with a cytotoxic drug, and m can be an integer or decimal from 1 to 8, such as , m can be about 1 to about 2, about 1 to about 3, about 1 to about 4, about 1 to about 5, about 1 to about 6, about 1 to about 7, or about 1 to about 8; for example, m can be about 2 to about 8, about 3 to about 8, about 4 to about 8, about 5 to about 8, about 6 to about 8, about 7 to about 8, or about 1, about 2, about 3, about 4, About 5, about 6, about 7 or about 8.
- the present application also provides a compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a mixture thereof
- a pharmaceutically acceptable salt, prodrug or solvate
- the compound comprises a structure selected from the group consisting of:
- Ab is a ligand capable of binding Trop-2, and m is a number from 1 to 8.
- the ligands described herein may be protein hormones, lectins, growth factors, antibodies, or other molecules capable of binding to cells, receptors and/or antigens.
- the ligand of the present application can be an anti-Trop-2 antibody or an antigen-binding fragment thereof.
- the ligand comprises at least one CDR in the variable region VL of the antibody light chain.
- the CDRs described in the present application may be defined according to Kabat; or may be defined according to Chothia, and the CDR sequences defined in various ways are all included within the protection scope of the present application.
- the antigen-binding protein of the present application may comprise CDR1-3 of the heavy chain variable region and CDR1-3 of the light chain variable region, wherein CDR1-3 of the heavy chain variable region and CDR1-3 of the light chain variable region 3 can be CDR1-3 of the heavy chain variable region and CDR1-3 of the light chain variable region of Sacituzumab, respectively.
- the antigen-binding protein of the present application may have the ability to bind to TROP2.
- the antigen binding protein of the present application can be a heavy chain variable region comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region can be the heavy chain variable region of Sacituzumab, respectively variable region and light chain variable region.
- the antigen-binding protein of the present application may have the ability to bind to TROP2.
- the antigen binding proteins of the present application may be comprised of heavy and light chains, wherein the heavy and light chains may be the heavy and light chains of Sacituzumab, respectively.
- the heavy chain amino acid sequence of Sacituzumab can be shown as SEQ ID NO:1
- the light chain amino acid sequence of Sacituzumab can be shown as SEQ ID NO:2.
- the ligands of the present application can be: for example, the heavy chain amino acid sequence of Sacituzumab can be as shown in SEQ ID NO: 1, ) light chain amino acid sequence can be as shown in SEQ ID NO:2.
- the heavy chain amino acid sequence of Trastuzumab can be shown in SEQ ID NO:3, and the light chain amino acid sequence of Trastuzumab can be shown in SEQ ID NO:4.
- the heavy chain amino acid sequence of Pertuzumab can be shown in SEQ ID NO:5, and the light chain amino acid sequence of Pertuzumab can be shown in SEQ ID NO:6.
- the heavy chain amino acid sequence of Enfortumab can be shown in SEQ ID NO:7, and the light chain amino acid sequence of Enfortumab can be shown in SEQ ID NO:8.
- the heavy chain amino acid sequence of Patritumab can be set forth in SEQ ID NO:9, and the light chain amino acid sequence of Patritumab can be set forth in SEQ ID NO:10.
- the heavy chain amino acid sequence of antibody H01L02 can be set forth in SEQ ID NO:11, and the light chain amino acid sequence of antibody H01L02 can be set forth in SEQ ID NO:12.
- Antibodies of the present application can be prepared using techniques well known in the art, such as hybridoma methods, recombinant DNA techniques, phage display techniques, synthetic techniques, or a combination of these techniques, or other techniques known in the art.
- Variants may refer to amino acid sequence mutants of antibodies, as well as covalent derivatives of the native polypeptide, provided that biological activity comparable to the native polypeptide is retained.
- Amino acid sequence mutants generally differ from the native amino acid sequence by the substitution of one or more amino acids in the native amino acid sequence or the deletion and/or insertion of one or more amino acids in the polypeptide sequence.
- Deletion mutants include fragments of the native polypeptide and N-terminal and/or C-terminal truncation mutants. Typically the amino acid sequence mutants have at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% or more homology compared to the native sequence.
- the drugs can be released into cells in an active form through the endocytosis of the conjugates or drug infiltration.
- the antibody-drug conjugate of the present application can be used to treat a target disease, and the antibody-drug conjugate of the present application can be administered to a subject (eg, a human) in a therapeutically effective amount through a suitable route.
- a subject in need of treatment may be a patient at risk, or suspected of having a disorder associated with the activity or level of expression of a particular antigen. Such patients can be identified by routine physical examination.
- delivery can be performed by methods routine in the art. For example, it can be introduced into cells by using liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, or bioadhesive microspheres.
- the nucleic acid or vector can be delivered locally by direct injection or by using an infusion pump.
- Other methods may include the use of various transport and carrier systems through the use of conjugates and biodegradable polymers.
- the application provides a pharmaceutical composition, which may contain the compound described in any one of the application, or a tautomer, meso, racemate, enantiomer, The diastereomers, or mixtures thereof, or pharmaceutically acceptable salts, prodrugs or solvates thereof, and may optionally contain a pharmaceutically acceptable carrier.
- the pharmaceutical composition described in the application may contain one or more excipients, which may be selected from the following group of ingredients: fillers (diluents), binders, wetting agents, disintegrating agents and excipients, etc.
- the composition may contain from 0.1 to 99% by weight of active compound.
- compositions containing the active ingredient may be in a form suitable for oral administration, such as tablets, dragees, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups.
- Oral compositions may be prepared according to any method known in the art for the preparation of pharmaceutical compositions, which may contain binders, fillers, lubricants, disintegrants or pharmaceutically acceptable wetting agents, etc.
- the composition may also contain one or more ingredients selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preservatives.
- Aqueous suspensions may contain the active materials in admixture with excipients suitable for the preparation of aqueous suspensions.
- the aqueous suspensions may also contain one or more preservatives, such as one or more coloring agents, one or more flavoring agents, and one or more sweetening agents.
- Oily suspensions can be formulated by suspending the active ingredient in vegetable oils.
- the oily suspensions may contain thickening agents. The above-mentioned sweetening and flavoring agents may also be added.
- the pharmaceutical compositions may also provide the active ingredient as dispersible powders and granules for preparation of aqueous suspensions by admixing with water one or more of a dispersing agent, wetting agent, suspending agent or preservative. Other excipients such as sweetening, flavouring and colouring agents may also be added. These compositions are preserved by the addition of antioxidants such as ascorbic acid.
- the pharmaceutical compositions of the present application may also be in the form of oil-in-water emulsions.
- the pharmaceutical compositions may be in the form of sterile injectable aqueous solutions.
- acceptable vehicles or solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- the sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oily phase.
- the active ingredient is dissolved in a mixture of soybean oil and lecithin.
- the oil solution can then be processed to form a microemulsion by adding it to a mixture of water and glycerol. Injections or microemulsions can be injected into a patient's bloodstream by local bolus injection.
- solutions and microemulsions can be administered in a manner that maintains a constant circulating concentration of the compounds of the application.
- a continuous intravenous drug delivery device can be used.
- the device may be an intravenous pump.
- compositions may be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned herein above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Alternatively, sterile fixed oils are conveniently employed as a solvent or suspending medium.
- the compounds of the present application may be administered in the form of suppositories for rectal administration.
- These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and therefore will melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, polyethylene glycols of various molecular weights and mixtures of fatty acid esters of polyethylene glycols.
- the dosage of a drug to be administered depends on a variety of factors including, but not limited to, the following factors: the activity of the particular compound used, the age of the patient, the weight of the patient, the health of the patient, the behavior of the patient , the patient's diet, administration time, administration mode, excretion rate, combination of drugs, etc.; in addition, the optimal treatment mode such as the mode of treatment, the compound or its tautomer, meso isomers, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, and/or compounds or tautomers, mesoisomers,
- the daily amount of racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, or the species of pharmaceutically acceptable salts can be verified according to conventional therapeutic regimens.
- the pharmaceutical composition of the present application may contain a safe and effective amount of the antibody-drug conjugate of the present application and a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier can include, but are not limited to, saline, buffers, dextrose, water, glycerol, ethanol, and combinations thereof.
- the pharmaceutical preparation should match the mode of administration, and the pharmaceutical composition of the present application can be prepared in the form of a solution, for example, prepared by a conventional method with a physiological saline or an aqueous solution containing glucose and other adjuvants.
- the pharmaceutical composition can be manufactured under sterile conditions.
- the active ingredient may be administered in a therapeutically effective amount.
- the effective amount of the antibody-drug conjugates described herein may vary with the mode of administration, the severity of the disease to be treated, and the like. Selection of an effective amount can be determined by one of ordinary skill in the art based on various factors (eg, through clinical trials). The factors may include, but are not limited to: the pharmacokinetic parameters of the diabody conjugate such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the weight of the patient, the immune status, route of administration, etc. Generally, when the antibody-drug conjugates of the present application are administered in an appropriate dose per day, satisfactory results can be obtained. For example, several divided doses may be administered daily or the dose may be proportionally reduced as dictated by the exigencies of the therapeutic situation.
- the compounds of the present application may be administered alone, or may be administered in combination with other pharmaceutically acceptable therapeutic agents.
- a safe and effective amount of the compound of the present application can be applied to a mammal (such as a human) in need of treatment, and the dose can be a pharmaceutically effective dose when administered, and the specific dose can also be considered. factors such as route, patient's health status, etc.
- the present application provides a compound of the present application, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable form thereof
- the tumor can be selected from tumors associated with expression of the following group of targets: HER2.
- the tumor associated with the expression of the target includes a tumor with high expression of the target and/or a tumor positive for the target.
- the tumor comprises a solid tumor and/or a hematological tumor.
- the tumor is selected from the group consisting of breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, Non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma and skin tumor.
- the present application provides a compound of the present application, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable form thereof Acceptable salts, prodrugs or solvates, and/or pharmaceutical compositions of the present application, which can be used for use in medicaments for the treatment and/or prevention of tumors.
- the tumor can be selected from tumors associated with expression of the following group of targets: HER2.
- the tumor associated with the expression of the target includes a tumor with high expression of the target and/or a tumor positive for the target.
- the tumor comprises a solid tumor and/or a hematological tumor.
- the tumor is selected from the group consisting of breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, Non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma and skin tumor.
- the present application provides a method of preventing and/or treating tumors, which may include administering to a subject a compound of the present application, or a tautomer, meso, racemate, enantiomer, A diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and/or the pharmaceutical composition of the present application.
- the tumor can be selected from tumors associated with expression of the following group of targets: HER2.
- the tumor associated with the expression of the target includes a tumor with high expression of the target and/or a tumor positive for the target.
- the tumor comprises a solid tumor and/or a hematological tumor.
- the tumor is selected from the group consisting of breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, Non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, glioma and skin tumor.
- Fmoc is 9-fluorenylmethoxycarbonyl protecting group (9-fluorenylmethyloxycarbonyl)
- Boc is tert-butoxycarbonyl protecting group (tert-butoxycarbonyl)
- TBDMS/TBS is tert-butyldimethylsilyl protecting group ( tert-butyldimethylsilyl).
- Fmoc-Val-OSu 100g, 229mmol was dissolved in 500ml of tetrahydrofuran, N ⁇ -(tert-butoxycarbonyl)-L-lysine (59.3g, 241mmol) and sodium bicarbonate (20.21g, 241mmol) were added respectively in 500 ml of aqueous solution.
- the reaction solution was stirred at room temperature for 48 hours, and the detection reaction was completed.
- the pH of the reaction solution was adjusted to about 6 with 1N dilute hydrochloric acid, and 500 ml of ethyl acetate was added for extraction.
- the organic phase was separated, washed once with water and saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness.
- compound (A-5) is the same as that of compound (A-4), except that the acetylated-10-polysarcosine (Ac-Sar10-COOH) in the last step is replaced by acetylated-4-polysarcosine Amino acid (Ac-Sar4-COOH), the product (A-5) is a beige amorphous powder after several steps of reaction.
- LC-MS (ESI, m/z) theoretical: 1330.60, found: 1331.61 (M+H).
- the intermediate compound 15-5 (150 mg, 0.131 mmol) was dissolved in 1 ml of anhydrous DMF, and acetylated-10 polysarcosine (Ac-Sar10-COOH) (101 mg, 0.131 mmol), DIPEA (114 ⁇ l, 0.654 mmol) and HATU (74.6 mg, 0.196 mmol), stirred at room temperature overnight, the solvent was removed under reduced pressure to obtain the final product, which was then prepared and purified by reverse-phase HPLC to obtain compound A-15 (107 mg, 0.059 mmol, yield 45.4%).
- LC-MS (ESI, m/z) theoretical: 1799.74, found: 1800.77 (M+H).
- the intermediate compound 15-5 (300 mg, 0.268 mmol) was dissolved in 5 ml of anhydrous DMF, and acetylated-10 polysarcosine (Ac-Sar10-COOH) (206 mg, 0.268 mmol), DIPEA (94 ⁇ l, 0.536 mmol) and HATU (122 mg, 0.321 mmol), stirred overnight at room temperature, and removed the solvent under reduced pressure to obtain the final product, which was then prepared and purified by reverse-phase HPLC to obtain compound A-18 (170 mg, 36% yield).
- LC-MS (ESI, m/z) theoretical: 1757.78, found: 1758.82 (M+H).
- Mc-Val-Cit-OH (purchased from Shanghai Haoyuan Chemical) reacts with bis(4-nitrophenyl) carbonate to obtain activated nitroester and further reacts with ixatecan methanesulfonic acid Salt (purchased from Shanghai Haoyuan) was reacted to obtain the reference compound MC-Val-Cit-PAB-DX8951.
- the antibody or antigen-binding fragment eg, a stock solution of Trastuzumab targeting HER2 (heavy chain sequence is shown in SEQ ID NO: 3, light chain sequence is shown in SEQ ID NO: 4) and/or, for example, targeting Trop-2.
- hRS7 mAb (Sacituzumab) in 50 mM potassium dihydrogen phosphate-sodium hydroxide (KH 2 PO4-NaOH)/150 mM sodium chloride (NaCl)/1 mM diethyltriaminepentaacetic acid (DTPA), pH 7 reaction buffer Dilute to 2 mg/mL, add tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in an excess molar ratio of 6.0 times, and stir the reaction solution at 35° C. for 2.5 hours.
- KH 2 PO4-NaOH potassium dihydrogen phosphate-sodium hydroxide
- NaCl sodium chloride
- DTPA diethyltriaminepentaacetic acid
- pH 7 reaction buffer Dilute to 2 mg/mL, add tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in an excess molar ratio of 6.0 times, and stir the reaction solution at 35°
- the above reaction solution was cooled to 8°C, an appropriate amount of dimethylacetamide (DMA) was added without purification, and then 6-15 times excess molar ratio of reference substance drug molecules or drug linker conjugates A1 to A29 ( 10 mg/ml pre-dissolved in DMA) to ensure that the volume ratio of DMA in the reaction system does not exceed 20%, and the coupling was performed by stirring at 37° C. for 3 hours.
- DMA dimethylacetamide
- the coupling reaction mixture was purified by gel filtration of pH 6.0 histidine-acetic acid/sucrose using a desalting column, and the peak samples were collected according to the UV280 absorption value. It was then sterilized through a 0.15 micron pore size filter and stored at -60°C.
- a 12-fold excess of compound (A-4) was conjugated with the reduced Trastuzumab monoclonal antibody to obtain antibody conjugate 4 with a drug loading (DAR) of about 7 to 8.
- DAR drug loading
- Size exclusion chromatography ( SEC-HPLC) to analyze the content of the polymer, and the analytical spectrum is shown in Figure 5.
- the proportion of aggregate 1 is about 0.3%.
- the drug loading (DAR) was about 7-8 by hydrophobic interaction high performance liquid chromatography (HIC-HPLC) analysis, and the analytical spectrum is shown in Figure 6.
- the hRS7 single-antigen solution targeting Trop-2 was dialyzed to 50mM sodium dihydrogen phosphate-disodium hydrogen phosphate (NaH 2 PO 4 -Na 2 HPO 4 )/50mM sodium chloride (NaCl), pH7.0 buffer middle. After measuring the concentration of mAb in the solution, dilute the antibody to 5 mg/mL with the above buffer. The reaction tube was placed in an ice bath to cool down for 10 minutes. Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was added in a molar ratio of 2.5 times, and the reaction solution was stirred at 4°C overnight.
- TCEP Tris(2-carboxyethyl)phosphine hydrochloride
- DMA dimethylacetamide
- a 6.0-fold excess molar ratio of the reference substance drug molecule or drug linker conjugate A-11 (10mM pre-dissolved in DMA) ensure that the volume ratio of DMA in the reaction system does not exceed 10%, and stir at 4 °C for 2 hours for coupling.
- a 4.0-fold molar ratio of Cysteine (Cysteine) small molecule was added to the reaction solution to consume the excess drug linker conjugate A-11, and the reaction was stirred at 4°C for 30 minutes for quenching.
- the coupling reaction mixture was purified by filtration with histidine-acetic acid/sodium chloride pH 5.5 using a desalting column, and the filtrated sample was collected.
- One-tenth volume of activated carbon-histidine-acetic acid/sodium chloride suspension (300 mg/mL) was added to the sample, and stirred at room temperature for 2 hours to fully absorb free small drug molecules. It was then sterilized through a 0.22 micron pore size filter and stored at -80°C.
- the content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analysis pattern was shown in Figure 25.
- the purity of the antibody conjugate 13 monomer was 98.95%.
- the conjugated drug concentration in the antibody-drug conjugate can be calculated by measuring the UV absorbance of the antibody-drug conjugate aqueous solution at two wavelengths of 280 nm and 370 nm, and then calculated as follows.
- the total absorbance at any given wavelength is equal to the sum of the absorbances of all light-absorbing chemicals in the system (absorption additivity). Therefore, based on the assumption that the molar absorption coefficient of the antibody and the drug does not change before and after conjugation of the antibody and the drug, the antibody concentration and the drug concentration in the antibody-drug conjugate are represented by the following formula.
- a 280 represents the absorbance of the antibody-drug conjugate solution at 280 nm
- a 370 represents the absorbance of the antibody-drug conjugate solution at 370 nm
- AD,280 represents the absorbance of the drug-linker conjugate at 280 nm
- AD,370 represents the absorbance of the drug-linker conjugate at 370 nm
- a A,280 represents the absorbance of the antibody at 280 nm
- a A,370 represents the absorbance of the antibody at 370 nm.
- ⁇ D,280 represents the molar absorption coefficient of the drug-linker conjugate at 280 nm
- ⁇ D,370 represents the molar absorption coefficient of the drug-linker conjugate at 370 nm
- ⁇ A,280 represents the molar absorption of the antibody at 280 nm
- the coefficient, ⁇ A, 370 represents the molar absorption coefficient of the antibody at 370 nm.
- CD represents the concentration of the drug linker conjugate in the antibody-drug conjugate solution
- CA represents the concentration of the antibody in the antibody-drug conjugate solution.
- ⁇ A,280 can be estimated from the amino acid sequence of the antibody by known computational methods (Protein Science, 1995, vol. 4, 2411-2423), and ⁇ A,370 is generally zero.
- ⁇ D,280 and ⁇ D,370 are obtained according to the Lambert-Beer law by the absorbance of the solution of the drug-linker conjugate at a certain molar concentration.
- the values of A 280 and A 370 are measured by a microplate reader or UV spectrophotometer, and the values of the above 4 molar absorption coefficients are put into the simultaneous equations (1) and (2), and C A and C can be calculated value of D.
- the average number of conjugated drug molecules in each antibody molecule DAR C D /C A .
- the hRS7 single-antigen solution targeting Trop-2 was dialyzed to 50mM sodium dihydrogen phosphate-disodium hydrogen phosphate (NaH 2 PO 4 -Na 2 HPO 4 )/50mM sodium chloride (NaCl), pH7.0 buffer middle. After measuring the concentration of mAb in the solution, dilute the antibody to 5 mg/mL with the above buffer. The reaction tube was placed in an ice bath to cool down for 10 minutes. Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was added in a molar ratio of 2.5 times, and the reaction solution was stirred at 4°C overnight.
- TCEP Tris(2-carboxyethyl)phosphine hydrochloride
- DMA dimethylacetamide
- the coupling reaction mixture was purified by filtration with histidine-acetic acid/sodium chloride pH 5.5 using a desalting column, and the filtrated sample was collected.
- One-tenth volume of activated carbon-histidine-acetic acid/sodium chloride suspension 300 mg/mL was added to the sample, and stirred at room temperature for 2 hours to fully absorb free small drug molecules. It was then sterilized through a 0.22 micron pore size filter and stored at -80°C.
- the content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analysis pattern was shown in Figure 26.
- the purity of the antibody conjugate 14 monomer was 98.20%.
- the hRS7 single-antigen solution targeting Trop-2 was dialyzed to 50mM sodium dihydrogen phosphate-disodium hydrogen phosphate (NaH 2 PO 4 -Na 2 HPO 4 )/50mM sodium chloride (NaCl), pH7.0 buffer middle. After measuring the concentration of mAb in the solution, dilute the antibody to 5 mg/mL with the above buffer. The reaction tube was placed in an ice bath to cool down for 10 minutes. Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was added in a molar ratio of 2.5 times, and the reaction solution was stirred at 4°C overnight.
- TCEP Tris(2-carboxyethyl)phosphine hydrochloride
- DMA dimethylacetamide
- the coupling reaction mixture was purified by filtration with histidine-acetic acid/sodium chloride pH 5.5 using a desalting column, and the filtrated sample was collected.
- One-tenth volume of activated carbon-histidine-acetic acid/sodium chloride suspension 300 mg/mL was added to the sample, and stirred at room temperature for 2 hours to fully absorb free small drug molecules. It was then sterilized through a 0.22 micron pore size filter and stored at -80°C.
- the content of the polymer was analyzed by size exclusion chromatography (SEC-HPLC), and the analysis pattern was shown in Figure 27.
- the purity of the antibody conjugate 15 monomer was 96.36%.
- ADC drugs based on camptothecin-like topoisomerase inhibitors such as Sacituzumab govitecan (Trodelvy) and Trastuzumab Deruxtecan (Enhertu) usually have a higher drug-to-antibody loading ratio (DAR), due to the aromatic concentration of camptothecin-like molecules.
- DAR drug-to-antibody loading ratio
- the ring-like structure has strong hydrophobicity, and the stability of such ADC molecules must be affected to a certain extent.
- the ADC prepared by the present invention introduces a polysarcosine peptide chain at a specific position, which has better "barrier effect" and may have better stability. We designed an antibody stability accelerated test to verify this hypothesis.
- Molecules compared include:
- the mobile phase of HPLC was 200 mM phosphate buffer (pH 7.0) + 150 mM KCl + 15% IPA, the column temperature was 25 °C, the injection volume was 7 ⁇ L, the flow rate was 0.75 ml/min, and the UV detection wavelengths were 280 nm and 370 nm.
- Human lung squamous cell carcinoma cells NCI-H2170 and LK-2, and human breast cancer cell MDA-MB-231 were selected as the cell lines for in vitro activity detection in this experiment, and the surface TROP2 antigen of the above human tumor cells was determined by flow cytometry (FACS).
- the expression level (expressed by rMFI), and the effect of antibody conjugate 13, DS-1062a (control drug, prepared according to the method described in US11173213B2), hIgG-deruxtecan conjugate, and hIgG-A-11 conjugate on cells was observed at the same time. The dose-response situation of killing.
- the final concentration of the antibody conjugated drug after adding the sample was set at 500nM as the initial concentration, and 500-0.1nM was designed in a series of 9 concentrations (5-fold ratio dilution), and the killing (or inhibition) changes were observed for 120 hours, and chemiluminescence staining (Luminescent Cell Viability Assay), IC 50 was calculated after reading the fluorescence data.
- both antibody conjugate 13 and DS-1062a can significantly inhibit the proliferation of tumor cells, which are significantly stronger than the negative and positive drugs IgG-deruxtecan conjugate and IgG A-1 conjugate.
- the inventive antibody conjugate 13 is significantly better than the clinical drug DS-1062a.
- the ADCs prepared from the compounds of the present application all show good in vitro anti-tumor activity, especially for tumor cells with low expression of related antigens.
- the antibody conjugates of the present application have more obvious advantages.
- the efficacy of the combinations of the invention can be measured in vivo, ie in rodents implanted with cancer cell allografts or xenografts, and treated with the combination.
- Test mice are treated with drug or control and monitored for several weeks or longer to measure time to tumor doubling, log cell killing, and tumor inhibition.
- Human lung squamous cell carcinoma cell NCI-H2170 (ATCC) was suspended in physiological saline, 4 ⁇ 10 7 cells were subcutaneously transplanted into the right flank of female nude mice, and grouping was performed at random on the sixth day. Taking the grouping day as the 0th day, on the 0th day, the antibody conjugate 13, DS-1062a (positive control drug) and hIgG-A-11 conjugate were respectively administered to the tail vein at a dose of 5 mg/kg as the negative control group.
- the ADCs prepared from the compounds of the present application all showed a certain anti-tumor activity in vivo, and could show significantly stronger anti-tumor activity compared with the control sample.
- the tumor-bearing mice tolerated the above drugs well, and no symptoms such as weight loss occurred.
Abstract
Description
Claims (43)
- 一种化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,其中所述化合物包含式(C-Trop-2)所示的结构:A compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt, pro- A drug or solvate, wherein the compound comprises a structure represented by the formula (C-Trop-2):其中,Q 1包含连接体, where Q1 contains the linker,L 1包含-L 1a-C(=O)-, L 1 contains -L 1a -C(=O)-,其中,L 1a选自以下组:任选取代的亚烷基、任选取代的聚乙二醇基、任选取代的亚烯基、任选取代的亚炔基、任选取代的亚脂环基、任选取代的亚脂杂环基、任选取代的亚芳基和任选取代的亚杂芳基; wherein, L 1a is selected from the group consisting of optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted alicyclic groups, optionally substituted alicyclic heterocyclyl groups, optionally substituted arylene groups, and optionally substituted heteroarylene groups;L 2包含任选取代的多肽残基, L2 comprises optionally substituted polypeptide residues,L 3包含任选取代的间隔基团, L 3 comprises an optionally substituted spacer group,其中,L 2和/或L 3包含任选取代的聚肌氨酸残基, wherein L 2 and/or L 3 comprise optionally substituted polysarcosine residues,T包含药物单元,T contains the drug unit,Ab为能够结合Trop-2的配体,m为1-8的数。Ab is a ligand capable of binding Trop-2, and m is a number from 1 to 8.
- 根据权利要求1所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of claim 1, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable form thereof an accepted salt, prodrug or solvate,其中,Q 1包含与巯基偶联后的连接体。 Wherein, Q 1 includes a linker coupled with a thiol group.
- 根据权利要求1-2中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-2, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,
- 根据权利要求1-3中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-3, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,L 1a选自以下组:任选取代的C 1-C 7的亚烷基、任选取代的二甘醇基至八甘醇基、任选取代的C 3-C 6亚脂环基、任选取代的亚芳基和任选取代的亚杂芳基。 wherein, L 1a is selected from the group consisting of optionally substituted C 1 -C 7 alkylene groups, optionally substituted diethylene glycol to octaethylene glycol groups, optionally substituted C 3 -C 6 alicyclic groups , optionally substituted arylene and optionally substituted heteroarylene.
- 根据权利要求1-4中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-4, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,L 1a选自以下组:任选取代的亚甲基、任选取代的亚乙基、任选取代的亚丙基、任选取代的亚丁基、任选取代的亚戊基、任选取代的二甘醇基、任选取代的四甘醇基、任选取代的六甘醇基、任选取代的八甘醇基和任选取代的亚环己基。 wherein L 1a is selected from the group consisting of optionally substituted methylene, optionally substituted ethylene, optionally substituted propylene, optionally substituted butylene, optionally substituted pentylene, optionally substituted Substituted diethylene glycol, optionally substituted tetraethylene glycol, optionally substituted hexaethylene glycol, optionally substituted octaethylene glycol, and optionally substituted cyclohexylene.
- 根据权利要求1-5中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-5, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,L 2包含任选取代的选自以下组的氨基酸构成的多肽残基:苯丙氨酸、异亮氨酸、亮氨酸、色氨酸、缬氨酸、甲硫氨酸、酪氨酸、丙氨酸、苏氨酸、组氨酸、丝氨酸、谷氨酰胺、精氨酸、赖氨酸、天冬酰胺、谷氨酸、脯氨酸、瓜氨酸、天冬氨酸和甘氨酸。 wherein L 2 comprises optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine acid, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid and glycine .
- 根据权利要求1-6中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-6, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,L 2包含任选取代的选自以下组的氨基酸构成的多肽残基:甘氨酸、苯丙氨酸、缬氨酸、丙氨酸、精氨酸、瓜氨酸、天冬氨酸、天冬酰胺和赖氨酸。 wherein L 2 comprises optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of: glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, amino acid Paraparagine and Lysine.
- 根据权利要求1-7中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-7, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,L 2包含任选取代的选自以下组的多肽残基:苯丙氨酸-赖氨酸(Phe-Lys)、缬氨酸-丙氨酸(Val-Ala)、缬氨酸-瓜氨酸(Val-Cit)、谷氨酸-缬氨酸-丙氨酸(Glu-Val-Ala)、谷氨酸-缬氨酸-瓜氨酸(Glu-Val-Cit)、缬氨酸-赖氨酸(Val-Lys)、丙氨酸-丙氨酸-丙氨酸(Ala-Ala-Ala)、丙氨酸-丙氨酸-天冬酰胺(Ala-Ala-Asn)和甘氨酸-甘氨酸-苯丙氨酸-甘氨酸(Gly-Gly-Phe-Gly)。 wherein L 2 comprises an optionally substituted polypeptide residue selected from the group consisting of phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline amino acid (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine- Lysine (Val-Lys), Alanine-Alanine-Alanine (Ala-Ala-Ala), Alanine-Alanine-Asparagine (Ala-Ala-Asn), and Glycine-Glycine - Phenylalanine-Glycine (Gly-Gly-Phe-Gly).
- 根据权利要求1-8中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-8, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,当L 2包含赖氨酸残基时,所述赖氨酸残基被包含聚肌氨酸残基的结构R 1取代。 Wherein, when L2 contains a lysine residue, the lysine residue is replaced by a structure R1 containing a polysarcosine residue.
- 根据权利要求9所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构 体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of claim 9, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable form thereof an accepted salt, prodrug or solvate,
- 根据权利要求10所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of claim 10, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable form thereof an accepted salt, prodrug or solvate,其中,n1为4至18。where n1 is 4 to 18.
- 根据权利要求1-11中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-11, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,
- 根据权利要求1-12中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-12, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,L 3的苯环与任选取代的聚肌氨酸残基通过结构单元-X-连接,结构单元-X-选自以下组:任选取代的 其中X 1选自以下组:羰基、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;其中X 2选自以下组:氢、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;其中X 3为共价键或选自以下组:氢、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;所述的C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基各自独立地任选地被选自氘代、卤素、氰基、硝基、氨基、烷基、羧基、烷氧基或环烷基的一个或者多个取代基取代。 Wherein, the benzene ring of L 3 is connected with the optionally substituted polysarcosine residue through the structural unit -X-, and the structural unit -X- is selected from the following group: optionally substituted wherein X 1 is selected from the group consisting of carbonyl, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and Linear-cyclic heteroalkyl groups containing 1-8 atoms containing 1-3 atoms selected from N, O or S ; wherein X is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkane containing 1-8 atoms group, the heteroalkyl group contains 1-3 atoms selected from N, O or S; wherein X 3 is a covalent bond or is selected from the following group: hydrogen, C 1 -C 8 alkyl, C 1 -C 8 Alkoxy, C1 - C6cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-cyclic-cyclic heteroalkyl containing 1-8 atoms, the heteroalkyl containing selected 1-3 atoms from N, O or S; said C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight containing 1-8 atoms Chain heteroalkyl, and straight-chain-cyclic heteroalkyl containing 1-8 atoms are each independently optionally selected from deuterated, halogen, cyano, nitro, amino, alkyl, carboxy, alkoxy substituted with one or more substituents of the radical or cycloalkyl.
- 根据权利要求1-13中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合 物,The compound of any one of claims 1-13, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,L 3的苯环与任选取代的聚肌氨酸残基通过结构单元-X-连接,结构单元-X-选自以下组:任选取代的 和任选取代的 其中X 1选自以下组:C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子,所述的C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基各自独立地任选地选自氘代、卤素、氰基、硝基、氨基、烷基、羧基、烷氧基或环烷基的一个或者多个取代基取代。 Wherein, the benzene ring of L 3 is connected with the optionally substituted polysarcosine residue through the structural unit -X-, and the structural unit -X- is selected from the following group: optionally substituted and optionally substituted wherein X 1 is selected from the group consisting of C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and containing 1 -8-atom straight-chain-cyclic heteroalkyl, said heteroalkyl containing 1-3 atoms selected from N, O or S, said C 1 -C 8 alkyl, C 1 -C 8 Alkoxy, C1 - C6cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkyl containing 1-8 atoms are each independently optionally selected from Substituted with one or more substituents of deuterated, halogen, cyano, nitro, amino, alkyl, carboxyl, alkoxy or cycloalkyl.
- 根据权利要求13-14中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 13-14, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,结构单元-X-为任选取代的 所述任选取代的聚肌氨酸残基包含 其中n2为4至18的数,R选自以下组:C 1-C 6烷基、C 1-C 6环烷基、和C 1-C 6烷氧基。 wherein the structural unit -X- is optionally substituted The optionally substituted polysarcosine residue comprises wherein n2 is a number from 4 to 18, and R is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, and C 1 -C 6 alkoxy.
- 根据权利要求13-15中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 13-15, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,结构单元-X-选自以下组:任选取代的 其中X 1选自以下组:羰基、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;其中X 2选自以下组:氢、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;其中X 3为共价键或选自以下组:氢、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;所述的C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基各自独立地任选地被选自氘代、卤素、氰基、硝基、氨 基、烷基、羧基、烷氧基或环烷基的一个或者多个取代基取代,所述任选取代的聚肌氨酸残基包含 其中n2为4至18的数,R选自以下组:C 1-C 6烷基、C 1-C 6环烷基、和C 1-C 6烷氧基。 wherein the structural unit -X- is selected from the group consisting of: optionally substituted wherein X 1 is selected from the group consisting of carbonyl, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and Linear-cyclic heteroalkyl groups containing 1-8 atoms containing 1-3 atoms selected from N, O or S ; wherein X is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkane containing 1-8 atoms group, the heteroalkyl group contains 1-3 atoms selected from N, O or S; wherein X 3 is a covalent bond or is selected from the following group: hydrogen, C 1 -C 8 alkyl, C 1 -C 8 Alkoxy, C1 - C6cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-cyclic-cyclic heteroalkyl containing 1-8 atoms, the heteroalkyl containing selected 1-3 atoms from N, O or S; said C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight containing 1-8 atoms Chain heteroalkyl, and straight-chain-cyclic heteroalkyl containing 1-8 atoms are each independently optionally selected from deuterated, halogen, cyano, nitro, amino, alkyl, carboxy, alkoxy substituted with one or more substituents of a radical or cycloalkyl, the optionally substituted polysarcosine residue comprising wherein n2 is a number from 4 to 18, and R is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, and C 1 -C 6 alkoxy.
- 根据权利要求13-14中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 13-14, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,结构单元-X-为任选取代的 所述任选取代的聚肌氨酸残基包含 其中n2为4至18的数,R选自以下组:C 1-C 6烷基、C 1-C 6环烷基、和C 1-C 6烷氧基。 wherein the structural unit -X- is optionally substituted The optionally substituted polysarcosine residue comprises wherein n2 is a number from 4 to 18, and R is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, and C 1 -C 6 alkoxy.
- 根据权利要求13-14和17中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 13-14 and 17, or a tautomer, meso, racemate, enantiomer, diastereomer, or tautomer thereof in the form of a mixture, or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,结构单元-X-选自以下组:任选取代的 其中X 1选自以下组:羰基、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;其中X 2选自以下组:氢、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;其中X 3为共价键或选自以下组:氢、C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基,所述杂烷基包含选自N、O或者S的1-3个原子;所述的C 1-C 8烷基、C 1-C 8烷氧基、C 1-C 6环烷基、包含1-8个原子的直链杂烷基、和包含1-8个原子的直链-环状杂烷基各自独立地任选地被选自氘代、卤素、氰基、硝基、氨基、烷基、羧基、烷氧基或环烷基的一个或者多个取代基取代,所述任选取代的聚肌氨酸残基包含 其中n2为4至18的数,R选自以下组:C 1-C 6烷基、C 1-C 6环烷基、 和C 1-C 6烷氧基。 wherein the structural unit -X- is selected from the group consisting of: optionally substituted wherein X 1 is selected from the group consisting of carbonyl, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight chain heteroalkyl containing 1-8 atoms, and Linear-cyclic heteroalkyl groups containing 1-8 atoms containing 1-3 atoms selected from N, O or S ; wherein X is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, linear heteroalkyl containing 1-8 atoms, and linear-cyclic heteroalkane containing 1-8 atoms group, the heteroalkyl group contains 1-3 atoms selected from N, O or S; wherein X 3 is a covalent bond or is selected from the following group: hydrogen, C 1 -C 8 alkyl, C 1 -C 8 Alkoxy, C1 - C6cycloalkyl, straight-chain heteroalkyl containing 1-8 atoms, and straight-cyclic-cyclic heteroalkyl containing 1-8 atoms, the heteroalkyl containing selected 1-3 atoms from N, O or S; said C 1 -C 8 alkyl, C 1 -C 8 alkoxy, C 1 -C 6 cycloalkyl, straight containing 1-8 atoms Chain heteroalkyl, and straight-chain-cyclic heteroalkyl containing 1-8 atoms are each independently optionally selected from deuterated, halogen, cyano, nitro, amino, alkyl, carboxy, alkoxy substituted with one or more substituents of a radical or cycloalkyl, the optionally substituted polysarcosine residue comprising wherein n2 is a number from 4 to 18, and R is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, and C 1 -C 6 alkoxy.
- 根据权利要求15-18中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 15-18, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,n2为4至18。where n2 is 4 to 18.
- 根据权利要求1-19中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-19, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,T包含具有抗肿瘤活性的化合物。Wherein, T comprises a compound with antitumor activity.
- 根据权利要求1-20中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-20, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,T包含拓扑异构酶抑制剂。where T comprises a topoisomerase inhibitor.
- 根据权利要求1-21中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-21, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中,T包含喜树碱类及非喜树碱类拓扑异构酶I抑制剂。Wherein, T includes camptothecin and non-camptothecin topoisomerase I inhibitors.
- 根据权利要求1-22中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-22, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,
- 根据权利要求1-23中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-23, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab包含抗Trop-2抗体或其抗原结合片段。wherein the Ab comprises an anti-Trop-2 antibody or an antigen-binding fragment thereof.
- 根据权利要求24所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of claim 24, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable form thereof an accepted salt, prodrug or solvate,其中所述抗体选自以下组:鼠源抗体、嵌合抗体、人源化抗体和全人源抗体。wherein the antibody is selected from the group consisting of murine antibodies, chimeric antibodies, humanized antibodies and fully human antibodies.
- 根据权利要求24-25中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 24-25, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述抗体包含单克隆抗体。wherein the antibody comprises a monoclonal antibody.
- 根据权利要求24-26中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 24-26, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述抗体包含双特异性抗体。wherein the antibody comprises a bispecific antibody.
- 根据权利要求24-27中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 24-27, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述抗原结合片段选自以下组:Fab,Fab′,Fv片段,F(ab') 2,F(ab) 2,scFv,di-scFv,VHH和dAb。 wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab', Fv fragments, F(ab') 2 , F(ab) 2 , scFv, di-scFv, VHH and dAb.
- 根据权利要求1-28中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-28, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab的重链HCDR1、HCDR2和HCDR3和轻链LCDR1、LCDR2和LCDR3分别包含抗Trop-2抗体的重链HCDR1、HCDR2和HCDR3和轻链LCDR1、LCDR2和LCDR3。Wherein the heavy chain HCDR1, HCDR2 and HCDR3 of the Ab and the light chain LCDR1, LCDR2 and LCDR3 respectively comprise the heavy chain HCDR1, HCDR2 and HCDR3 and the light chain LCDR1, LCDR2 and LCDR3 of the anti-Trop-2 antibody.
- 根据权利要求1-29中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-29, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab的重链HCDR1、HCDR2和HCDR3和轻链LCDR1、LCDR2和LCDR3分别包含hRS7的重链HCDR1、HCDR2和HCDR3和轻链LCDR1、LCDR2和LCDR3。Wherein the heavy chain HCDR1, HCDR2 and HCDR3 and the light chain LCDR1, LCDR2 and LCDR3 of the Ab respectively comprise the heavy chain HCDR1, HCDR2 and HCDR3 and the light chain LCDR1, LCDR2 and LCDR3 of hRS7.
- 根据权利要求1-30中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-30, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab的重链可变区VH和轻链可变区VL分别包含抗Trop-2抗体的重链可变区VH和轻链可变区VL。The heavy chain variable region VH and the light chain variable region VL of the Ab respectively comprise the heavy chain variable region VH and the light chain variable region VL of the anti-Trop-2 antibody.
- 根据权利要求1-31中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-31, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab的重链可变区VH和轻链可变区VL分别包含hRS7的重链可变区VH和轻链可变区VL。The heavy chain variable region VH and the light chain variable region VL of the Ab respectively comprise the heavy chain variable region VH and the light chain variable region VL of hRS7.
- 根据权利要求1-32中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-32, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab的重链和轻链分别包含抗Trop-2抗体的重链和轻链。wherein the heavy chain and light chain of the Ab comprise the heavy chain and light chain of an anti-Trop-2 antibody, respectively.
- 根据权利要求1-33中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-33, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab的重链和轻链分别包含hRS7的重链和轻链。wherein the heavy chain and light chain of the Ab respectively comprise the heavy chain and light chain of hRS7.
- 根据权利要求1-34中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-34, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述Ab包含hRS7。wherein the Ab comprises hRS7.
- 根据权利要求1-35中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,The compound of any one of claims 1-35, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof,其中所述m通过选自以下组的方法测定:疏水层析、十二烷基硫酸钠聚丙烯酰胺凝胶电泳和液相质谱。wherein the m is determined by a method selected from the group consisting of hydrophobic chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, and liquid phase mass spectrometry.
- 一种化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,A compound, or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt, pro- drug or solvate,其中,所述化合物包含选自以下组的结构:wherein the compound comprises a structure selected from the group consisting of:Ab为能够结合Trop-2的配体,m为1-8的数。Ab is a ligand capable of binding Trop-2, and m is a number from 1 to 8.
- 一种药物组合物,其含有权利要求1-37中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,以及任选地药学上可接受的载体。A pharmaceutical composition comprising the compound of any one of claims 1-37, or a tautomer, meso, racemate, enantiomer, diastereomer, or tautomer thereof The form, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and optionally a pharmaceutically acceptable carrier.
- 含有权利要求1-37中任一项所述的化合物,或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其药学上可接受的盐、前药或溶剂合物,和/或权利要求38所述的药物组合物在制备用于治疗和/或预防肿瘤的药物中的用途。Contains the compound of any one of claims 1-37, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof , or a pharmaceutically acceptable salt, prodrug or solvate thereof, and/or the use of the pharmaceutical composition of claim 38 in the preparation of a medicament for treating and/or preventing tumors.
- 根据权利要求39所述的用途,所述肿瘤与Trop-2表达相关的肿瘤。The use of claim 39, wherein the tumor is a tumor associated with Trop-2 expression.
- 根据权利要求40所述的用途,所述与所述靶点表达相关的肿瘤包含所述靶点高表达的肿瘤和/或所述靶点阳性的肿瘤。The use according to claim 40, wherein the tumor associated with the expression of the target comprises a tumor with high expression of the target and/or a tumor positive for the target.
- 根据权利要求39-41中任一项所述的用途,所述肿瘤包含实体肿瘤和/或血液肿瘤。The use of any one of claims 39-41, wherein the tumor comprises a solid tumor and/or a hematological tumor.
- 根据权利要求39-42中任一项所述的用途,所述肿瘤选自以下组:肺癌、尿道癌、大肠癌、前列腺癌、卵巢癌、胰腺癌、乳腺癌、膀胱癌、胃癌、胃肠道间质瘤、宫颈癌、食 道癌、鳞状细胞癌、腹膜癌、肝癌、肝细胞癌、结肠癌、直肠癌、结肠直肠癌、子宫内膜癌、子宫癌、唾液腺癌、肾癌、外阴癌、甲状腺癌、阴茎癌、白血病、恶性淋巴瘤、浆细胞瘤、骨髓瘤、或肉瘤。肺癌、尿道癌、大肠癌、前列腺癌、卵巢癌、胰腺癌、乳腺癌、膀胱癌、胃癌、胃肠道间质瘤、宫颈癌、食道癌、鳞状细胞癌、腹膜癌、肝癌、肝细胞癌、结肠癌、直肠癌、结肠直肠癌、子宫内膜癌、子宫癌、唾液腺癌、肾癌、外阴癌、甲状腺癌、阴茎癌、白血病、恶性淋巴瘤、浆细胞瘤、骨髓瘤、和肉瘤。The use according to any one of claims 39-42, wherein the tumor is selected from the group consisting of lung cancer, urethral cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, stomach cancer, gastrointestinal cancer Stromal tumor, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulva cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, or sarcoma. Lung cancer, urethral cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, stomach cancer, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, squamous cell cancer, peritoneal cancer, liver cancer, hepatocyte cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, and sarcoma .
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3173902A CA3173902A1 (en) | 2021-04-29 | 2022-04-28 | Preparation method and application of antibody drug conjugate |
CN202280030781.1A CN117337195A (en) | 2021-04-29 | 2022-04-28 | Preparation method and application of antibody coupling drug |
EP22794965.8A EP4331613A1 (en) | 2021-04-29 | 2022-04-28 | Preparation method for antibody-drug conjugate, and application |
KR1020237041142A KR20240006029A (en) | 2021-04-29 | 2022-04-28 | Manufacturing method and application of antibody-drug conjugate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110475315 | 2021-04-29 | ||
CN202110475315.1 | 2021-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022228495A1 true WO2022228495A1 (en) | 2022-11-03 |
Family
ID=83846703
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/089726 WO2022228495A1 (en) | 2021-04-29 | 2022-04-28 | Preparation method for antibody-drug conjugate, and application |
PCT/CN2022/089724 WO2022228493A1 (en) | 2021-04-29 | 2022-04-28 | Preparation method and application of antibody drug conjugate |
PCT/CN2022/089725 WO2022228494A1 (en) | 2021-04-29 | 2022-04-28 | Preparation method for and application of antibody conjugated drug |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/089724 WO2022228493A1 (en) | 2021-04-29 | 2022-04-28 | Preparation method and application of antibody drug conjugate |
PCT/CN2022/089725 WO2022228494A1 (en) | 2021-04-29 | 2022-04-28 | Preparation method for and application of antibody conjugated drug |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP4331611A1 (en) |
KR (2) | KR20240006028A (en) |
CN (3) | CN117241834A (en) |
AU (1) | AU2022263700A1 (en) |
CA (3) | CA3173902A1 (en) |
IL (1) | IL308025A (en) |
TW (3) | TW202309045A (en) |
WO (3) | WO2022228495A1 (en) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
US20060275305A1 (en) | 2005-05-13 | 2006-12-07 | Bryant John L | HERCEPTIN adjuvant therapy |
CN102174105B (en) | 2005-12-30 | 2013-09-25 | U3制药有限公司 | Antibodies directed to HER-3 and uses thereof |
WO2014172371A2 (en) | 2013-04-16 | 2014-10-23 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
CN105102455A (en) * | 2012-12-21 | 2015-11-25 | 荷商台医(有限合伙)公司 | Hydrophilic self-immolative linkers and conjugates thereof |
WO2016038383A1 (en) | 2014-09-12 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2017042210A1 (en) | 2015-09-09 | 2017-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
CN108066772A (en) * | 2016-11-14 | 2018-05-25 | 中国科学院上海药物研究所 | Target the antibody of TACSTD2 and drug coupling body (ADC) molecule |
WO2018212136A1 (en) | 2017-05-15 | 2018-11-22 | 第一三共株式会社 | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate |
CN111542344A (en) * | 2017-10-23 | 2020-08-14 | 马布林克生物科学公司 | Ligand-drug-conjugates comprising a single molecular weight polymyosine |
WO2020236841A2 (en) * | 2019-05-20 | 2020-11-26 | Novartis Ag | Antibody drug conjugates having linkers comprising hydrophilic groups |
WO2020233174A1 (en) | 2019-05-20 | 2020-11-26 | 烟台迈百瑞国际生物医药有限公司 | One-pot preparation process for antibody drug conjugate intermediate |
US11173213B2 (en) | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105722851A (en) * | 2013-04-28 | 2016-06-29 | 秦刚 | Novel linker and preparation method thereof |
KR102511249B1 (en) * | 2014-04-29 | 2023-03-20 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | New stable antibody-drug conjugate, preparation method therefor, and use thereof |
-
2022
- 2022-04-28 CN CN202280030774.1A patent/CN117241834A/en active Pending
- 2022-04-28 CA CA3173902A patent/CA3173902A1/en active Pending
- 2022-04-28 KR KR1020237041141A patent/KR20240006028A/en unknown
- 2022-04-28 CA CA3173511A patent/CA3173511A1/en active Pending
- 2022-04-28 EP EP22794963.3A patent/EP4331611A1/en active Pending
- 2022-04-28 TW TW111116233A patent/TW202309045A/en unknown
- 2022-04-28 TW TW111116237A patent/TW202308701A/en unknown
- 2022-04-28 EP EP22794964.1A patent/EP4331612A1/en active Pending
- 2022-04-28 AU AU2022263700A patent/AU2022263700A1/en active Pending
- 2022-04-28 TW TW111116236A patent/TW202308700A/en unknown
- 2022-04-28 WO PCT/CN2022/089726 patent/WO2022228495A1/en active Application Filing
- 2022-04-28 WO PCT/CN2022/089724 patent/WO2022228493A1/en active Application Filing
- 2022-04-28 EP EP22794965.8A patent/EP4331613A1/en active Pending
- 2022-04-28 KR KR1020237041142A patent/KR20240006029A/en unknown
- 2022-04-28 CN CN202280030770.3A patent/CN117241833A/en active Pending
- 2022-04-28 CA CA3173758A patent/CA3173758A1/en active Pending
- 2022-04-28 CN CN202280030781.1A patent/CN117337195A/en active Pending
- 2022-04-28 IL IL308025A patent/IL308025A/en unknown
- 2022-04-28 WO PCT/CN2022/089725 patent/WO2022228494A1/en active Application Filing
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
US20060275305A1 (en) | 2005-05-13 | 2006-12-07 | Bryant John L | HERCEPTIN adjuvant therapy |
CN102174105B (en) | 2005-12-30 | 2013-09-25 | U3制药有限公司 | Antibodies directed to HER-3 and uses thereof |
CN105102455A (en) * | 2012-12-21 | 2015-11-25 | 荷商台医(有限合伙)公司 | Hydrophilic self-immolative linkers and conjugates thereof |
WO2014172371A2 (en) | 2013-04-16 | 2014-10-23 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
WO2016038383A1 (en) | 2014-09-12 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11173213B2 (en) | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
WO2017042210A1 (en) | 2015-09-09 | 2017-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
CN108066772A (en) * | 2016-11-14 | 2018-05-25 | 中国科学院上海药物研究所 | Target the antibody of TACSTD2 and drug coupling body (ADC) molecule |
WO2018212136A1 (en) | 2017-05-15 | 2018-11-22 | 第一三共株式会社 | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate |
US20200171163A1 (en) | 2017-05-15 | 2020-06-04 | Daiichi Sankyo Company, Limited | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate |
CN111542344A (en) * | 2017-10-23 | 2020-08-14 | 马布林克生物科学公司 | Ligand-drug-conjugates comprising a single molecular weight polymyosine |
WO2020236841A2 (en) * | 2019-05-20 | 2020-11-26 | Novartis Ag | Antibody drug conjugates having linkers comprising hydrophilic groups |
WO2020233174A1 (en) | 2019-05-20 | 2020-11-26 | 烟台迈百瑞国际生物医药有限公司 | One-pot preparation process for antibody drug conjugate intermediate |
Non-Patent Citations (6)
Title |
---|
"Uniprot", Database accession no. Q96NY8 |
CAS , no. 529488-28-6 |
CAS, no. 171335-80-1 |
CONILH LOUISE, FOURNET GUY, FOURMAUX ERIC, MURCIA ANGÉLIQUE, MATERA EVA-LAURE, JOSEPH BENOÎT, DUMONTET CHARLES, VIRICEL WARREN: "Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform", PHARMACEUTICALS, vol. 14, no. 3, 9 March 2021 (2021-03-09), CH , pages 247, XP055953984, ISSN: 1424-8247, DOI: 10.3390/ph14030247 * |
PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423 |
VIRICEL WARREN, FOURNET GUY, BEAUMEL SABINE, PERRIAL EMELINE, PAPOT SÉBASTIEN, DUMONTET CHARLES, JOSEPH BENOÎT: "Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates", CHEMICAL SCIENCE, ROYAL SOCIETY OF CHEMISTRY, vol. 10, no. 14, 3 April 2019 (2019-04-03), United Kingdom , pages 4048 - 4053, XP055981921, ISSN: 2041-6520, DOI: 10.1039/C9SC00285E * |
Also Published As
Publication number | Publication date |
---|---|
CA3173758A1 (en) | 2022-11-03 |
EP4331612A1 (en) | 2024-03-06 |
CN117241834A (en) | 2023-12-15 |
WO2022228494A1 (en) | 2022-11-03 |
EP4331611A1 (en) | 2024-03-06 |
CN117337195A (en) | 2024-01-02 |
IL308025A (en) | 2023-12-01 |
AU2022263700A1 (en) | 2023-11-16 |
TW202308700A (en) | 2023-03-01 |
TW202309045A (en) | 2023-03-01 |
KR20240006028A (en) | 2024-01-12 |
CN117241833A (en) | 2023-12-15 |
WO2022228493A1 (en) | 2022-11-03 |
CA3173902A1 (en) | 2022-11-03 |
TW202308701A (en) | 2023-03-01 |
EP4331613A1 (en) | 2024-03-06 |
CA3173511A1 (en) | 2023-10-28 |
KR20240006029A (en) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108101825B (en) | Disubstituted maleimide linker for antibody-drug coupling, preparation method and application thereof | |
TWI757759B (en) | Cytotoxic benzodiazepine derivatives | |
JP6947630B2 (en) | Biological substances and their use | |
EP3546448B1 (en) | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof | |
TW202146057A (en) | Conjugates of cysteine engineered antibodies | |
JP2020141700A (en) | Cd48 antibodies and conjugates thereof | |
JP6782250B2 (en) | Bifunctional cytotoxic agent containing CTI pharmacophore | |
CN115955980A (en) | Variable charge joint | |
JP2023036874A (en) | Methods of preventing methionine oxidation in immunoconjugates | |
WO2022228495A1 (en) | Preparation method for antibody-drug conjugate, and application | |
KR20240022626A (en) | Antitumor compounds and their applications | |
JP2022500454A (en) | Combination therapy with antifolate receptor antibody conjugate | |
TW202313123A (en) | Anthracycline antibody conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22794965 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18557454 Country of ref document: US Ref document number: 2023566660 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20237041142 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022794965 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022794965 Country of ref document: EP Effective date: 20231129 |